A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
Proteins prepared by recombinant DNA technology.
Receptors that bind and internalize GRANULOCYTE COLONY-STIMULATING FACTOR. Their MW is believed to be 150 kD. These receptors are found mainly on a subset of myelomonocytic cells.
A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS.
Glycoproteins found in a subfraction of normal mammalian plasma and urine. They stimulate the proliferation of bone marrow cells in agar cultures and the formation of colonies of granulocytes and/or macrophages. The factors include INTERLEUKIN-3; (IL-3); GRANULOCYTE COLONY-STIMULATING FACTOR; (G-CSF); MACROPHAGE COLONY-STIMULATING FACTOR; (M-CSF); and GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; (GM-CSF).
CELL LINE derived from the ovary of the Chinese hamster, Cricetulus griseus (CRICETULUS). The species is a favorite for cytogenetic studies because of its small chromosome number. The cell line has provided model systems for the study of genetic alterations in cultured mammalian cells.
Substances and drugs that lower the SURFACE TENSION of the mucoid layer lining the PULMONARY ALVEOLI.
A bibliographic database that includes MEDLINE as its primary subset. It is produced by the National Center for Biotechnology Information (NCBI), part of the NATIONAL LIBRARY OF MEDICINE. PubMed, which is searchable through NLM's Web site, also includes access to additional citations to selected life sciences journals not in MEDLINE, and links to other resources such as the full-text of articles at participating publishers' Web sites, NCBI's molecular biology databases, and PubMed Central.
An acidic glycoprotein of MW 23 kDa with internal disulfide bonds. The protein is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages.
A publication issued at stated, more or less regular, intervals.
"The business or profession of the commercial production and issuance of literature" (Webster's 3d). It includes the publisher, publication processes, editing and editors. Production may be by conventional printing methods or by electronic publishing.
The premier bibliographic database of the NATIONAL LIBRARY OF MEDICINE. MEDLINE® (MEDLARS Online) is the primary subset of PUBMED and can be searched on NLM's Web site in PubMed or the NLM Gateway. MEDLINE references are indexed with MEDICAL SUBJECT HEADINGS (MeSH).
Receptors that bind and internalize the granulocyte-macrophage stimulating factor. Their MW is believed to be 84 kD. The most mature myelomonocytic cells, specifically human neutrophils, macrophages, and eosinophils, express the highest number of affinity receptors for this growth factor.
A multilineage cell growth factor secreted by LYMPHOCYTES; EPITHELIAL CELLS; and ASTROCYTES which stimulates clonal proliferation and differentiation of various types of blood and tissue cells.
A mononuclear phagocyte colony-stimulating factor (M-CSF) synthesized by mesenchymal cells. The compound stimulates the survival, proliferation, and differentiation of hematopoietic cells of the monocyte-macrophage series. M-CSF is a disulfide-bonded glycoprotein dimer with a MW of 70 kDa. It binds to a specific high affinity receptor (RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR).
A TCF transcription factor that was originally identified as a DNA-binding protein that interacts with the enhancers of T-CELL RECEPTOR ALPHA GENES. It plays a role in T-LYMPHOCYTE development.
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
An enzyme capable of hydrolyzing highly polymerized DNA by splitting phosphodiester linkages, preferentially adjacent to a pyrimidine nucleotide. This catalyzes endonucleolytic cleavage of DNA yielding 5'-phosphodi- and oligonucleotide end-products. The enzyme has a preference for double-stranded DNA.
Infection with flukes (trematodes) of the genus SCHISTOSOMA. Three species produce the most frequent clinical diseases: SCHISTOSOMA HAEMATOBIUM (endemic in Africa and the Middle East), SCHISTOSOMA MANSONI (in Egypt, northern and southern Africa, some West Indies islands, northern 2/3 of South America), and SCHISTOSOMA JAPONICUM (in Japan, China, the Philippines, Celebes, Thailand, Laos). S. mansoni is often seen in Puerto Ricans living in the United States.
The branch of medicine concerned with diseases, mainly of parasitic origin, common in tropical and subtropical regions.
A country in northern Africa, bordering the Mediterranean Sea, between Libya and the Gaza Strip, and the Red Sea north of Sudan, and includes the Asian Sinai Peninsula Its capital is Cairo.
Marine, freshwater, or terrestrial mollusks of the class Gastropoda. Most have an enclosing spiral shell, and several genera harbor parasites pathogenic to man.
A genus of trematode flukes belonging to the family Schistosomatidae. There are over a dozen species. These parasites are found in man and other mammals. Snails are the intermediate hosts.
The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.
Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes.
A method, developed by Dr. Virginia Apgar, to evaluate a newborn's adjustment to extrauterine life. Five items - heart rate, respiratory effort, muscle tone, reflex irritability, and color - are evaluated 60 seconds after birth and again five minutes later on a scale from 0-2, 0 being the lowest, 2 being normal. The five numbers are added for the Apgar score. A score of 0-3 represents severe distress, 4-7 indicates moderate distress, and a score of 7-10 predicts an absence of difficulty in adjusting to extrauterine life.

Establishment of an inducible expression system of chimeric MLL-LTG9 protein and inhibition of Hox a7, Hox b7 and Hox c9 expression by MLL-LTG9 in 32Dcl3 cells. (1/3327)

The MLL (HRX/ALL-1 gene is frequently disrupted in infantile leukemias and therapy-related leukemias and fused to various translocation partner genes. We previously showed that chimeric MLL proteins localize in the nuclei in a fashion similar to that of MLL protein even if the partner gene encodes a cytoplasmic protein and indicated the importance of the N-terminal portion of MLL common to various MLL translocations. This time we established an inducible expression system for chimeric MLL-LTG9 and truncated N-terminal MLL proteins (MLL-Zf(-)) in 32Dcl3 cells. By utilizing this system, we were able to show inhibition of Hox a7, Hox b7 and Hox c9 genes' expression by induced MLL-LTG9 and MLL-Zf(-). Up-regulation of Hox a7, Hox b7 and Hox c9 was observed when 32Dcl3 cells were cultured with granulocyte colony stimulating factor (G-CSF) in place of interleukin 3 and induction of MLL-LTG9 and MLL-Zf(-) was shown to suppress this upregulation. At the same time, expression of two mammalian Polycomb group genes, M33 and mel-18, which both reportedly affect Hox genes' expression, was not inhibited by MLL-LTG9 and MLL-Zf(-) induction. These results indicate that MLL has an important effect on the expression of at least some Hox genes in hematopoietic cells and suggest that inhibition of the proper expression of Hox genes by chimeric MLL proteins may dysregulate hematopoietic cell differentiation and proliferation, which then can lead to leukemogenesis.  (+info)

Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). (2/3327)

Twenty-two patients, with locally advanced unresectable and/or metastatic pancreatic carcinoma, received weekly administration of cisplatin 40 mg m(-2), 5-fluorouracil 500 mg m(-2), epidoxorubicin 35 mg m(-2), 6S stereoisomer of leucovorin 250 mg m(-2) and glutathione 1.5 mg m(-2), supported by a daily administration of lenograstim at a dose of 5 microg kg(-1). Nineteen patients were men and three were women. Median age was 63 years (range 47-70). At study entry, pain was present in 15 out of 22 patients (68%) with a mean value of Scott-Huskisson scale of 27.6+/-23.8, whereas a weight loss >10% was present in 15 patients. After eight weekly treatments, three partial responses were achieved for a response rate of 13% (95% CI 0-26%), five patients had stable disease and 14 progressed on therapy. Pain was present in 9 out of 22 patients (40%) with a mean value of Scott-Huskisson scale of 12.3+/-18.4. Eight patients (36%) (three partial response and five stable disease) had a positive weight change. Toxicity was mild: WHO grade III or IV toxicity was recorded in terms of anaemia in 7 out of 188 cycles (3.7%), of neutropenia in 9 out of 188 cycles (4.7%) and of thrombocytopenia in 3 out of 188 cycles (1.5%). Median survival of all patients was 6 months. The outcome of this intensive chemotherapy regimen does not support its use in pancreatic cancer.  (+info)

Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF. (3/3327)

We have evaluated the immunophenotype, functional activity and clonogenic potential of CD34+ cells from peripheral blood (PB) of normal donors before and after 4 and 6 days of G-CSF administration. The percentage and absolute number of CD34+ cells significantly increased at days 4 and 6 of G-CSF administration, compared to the steady-state level (P < 0.0001). Two-colour fluorescence analysis showed, at days 4 and 6, a lower proportion of CD34+/c-kit+ compared to the steady-state level (P < 0.0001), but a similar expression of CD13, CD33, CD38, HLA-DR and Thy-1 antigens on CD34+ cells. The expression of adhesion molecules on CD34+ cells revealed a significant reduction of CD11a (P = 0.009), CD18, CD49d and CD62L (P < 0.0001) at days 4 and 6, compared to the baseline level. Three-colour staining showed a reduction of the more immature compartment (34+/DR-/13-) and an increase of the more differentiated compartment (34+/DR+/13+). Downregulation of VLA-4 during mobilisation was seen almost exclusively on more committed cells (34+/13+); downregulation of CD62L, on the contrary, was observed on both early progenitors (34+/13-) and more committed cells (34+/13+). The expression of 34+/VLA-4+ decreased on both c-kit+ and c-kit- cells, while the expression of 34+/62L+ decreased on the c-kit+ cells only. In vivo administration of G-CSF reduced the adherence capacity of CD34+ cells to normal BM stroma; in vitro incubation with SCF or IL-3 enhanced the expression of CD49d on CD34+ cells, while GM-CSF reduced the expression of CD62L. SCF was the only cytokine able to induce a significant increase of CD34+ cell adherence to preformed stroma. Pre-incubation with the blocking beta2 integrin monoclonal antibody caused a reduction of CD34+ cell adherence. In conclusion, the decrease of CD49d expression on mobilized CD34+ cells correlates with a poor adhesion to BM stroma; CD34+ cells incubated in vitro with SCF showed, conversely, a higher expression of CD49d and a greater adherence capacity on normal preformed stroma.  (+info)

Effects of short-term administration of G-CSF (filgrastim) on bone marrow progenitor cells: analysis of serial marrow samples from normal donors. (4/3327)

To determine the effect of G-CSF administration on both the total number of CD34+ cells and the primitive CD34+ subsets in bone marrow (BM), we have analyzed BM samples serially obtained from 10 normal donors in steady-state and during G-CSF treatment. Filgrastim was administered subcutaneously at a dosage of 10 microg/kg/day (n = 7) or 10 microg/kg/12 h (n = 3) for 4 consecutive days. Peripheral blood sampling and BM aspirates were performed on day 1 (just before G-CSF administration), day 3 (after 2 days of G-CSF), and day 5 (after 4 days of G-CSF). During G-CSF administration, a significant increase in the total number of BM nucleated cells was observed. The percentage (range) of CD34+ cells decreased in BM from a median of 0.88 (0.47-1.44) on day 1 to 0.57 (0.32-1.87), and to 0.42 (0.16-0.87) on days 3 and 5, respectively. We observed a slight increase in the total number of BM CD34+ cells on day 3 (0.66 x 10(9)/l (0.13-0.77)), and a decrease on day 5 (0.23 x 10(9)/l (0.06-1.23)) as compared with steady-state (0.40 x 10(9)/l (0.06-1.68)). The proportion of primitive BM hematopoietic progenitor cells (CD34+CD38-, CD34+HLA-DR-, CD34+CD117-) decreased during G-CSF administration. In parallel, a significant increase in the total number of CD34+ cells in peripheral blood was observed, achieving the maximum value on day 5. These results suggest that in normal subjects the administration of G-CSF for 5 days may reduce the number of progenitor cells in BM, particularly the most primitive ones.  (+info)

Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs G-CSF mobilized PSC products. (5/3327)

This study compares the immune properties of peripheral blood stem cell (PSC) products mobilized with different hematopoietic growth factors (HGFs) as well as apheresis products and peripheral blood leukocytes (PBL) from normal individuals. We found that monocytes in mobilized PSC products appear to inhibit T cell function independent of whether granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) was used for mobilization. In addition, the GF used to mobilize the stem cell product may be less important to the CD4:CD8 ratio than the extent of prior chemotherapy, as we found an inverse correlation between chemotherapy and the CD4:CD8 ratio. In other observations, all apheresis products, whether mobilized or unmobilized, contained significantly more monocytes compared to normal PBL. The mononuclear cells (MNC) from G-CSF or GM-CSF mobilized PSC products had a similar T cell phytohemagglutinin (PHA) mitogenic response that was significantly lower (P = 0.001 and P = 0.005, respectively) than non-mobilized apheresis products. We also examined the T cell inhibitor (TI) activity of the MNC from the PSC products for allogeneic lymphocyte proliferation and found that PSC products significantly reduced the proliferation of allogeneic PBL to PHA. A significant correlation (P = 0.001, r = 0.517) between the frequency of monocytes and TI activity also was observed.  (+info)

Advances in the biological therapy and gene therapy of malignant disease. (6/3327)

Biological and gene therapy of cancer have become important components of clinical cancer research. Advances in this area are based on evidence for the presence of tumor antigens, antitumor immune responses, evasion of host control by tumors, and the recognition of host defense failure in cancer patients. These mechanisms are being corrected or exploited in the development of biological and gene therapy. Over the last decade, 9 biological therapies have received Food and Drug Administration approval, and another 12 appear promising and will likely be approved in the next few years. Our approach to gene therapy has been to allogenize tumors by the direct intratumoral injection of HLA-B7/beta2-microglobulin genes as plasmid DNA in a cationic lipid into patients with malignant melanoma. In four Phase I studies, we found a 36% response by the local injected tumor and a 19% systemic antitumor response. In other cancers, gene transfer, expression, and an intratumoral T-cell response were seen, but no clinical response was seen. A variety of follow-up studies with HLA-B7 and other genes are planned. Evasion of host control is now a major target of gene therapy. Strategies to overcome this include up-regulation of MHC and introduction of cell adhesion molecules into tumor cells, suppression of transforming growth factor and interleukin 10 production by tumor cells, and blockade of the fas ligand-fas interaction between tumor cells and attacking lymphocytes. With these approaches, it seems likely that gene therapy may become the fifth major modality of cancer treatment in the next decade.  (+info)

Comparison of interferon-gamma, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens. (7/3327)

Proinflammatory cytokines have been proposed as adjunctive therapeutic agents to enhance the host immune response during infections caused by opportunistic fungi. The study compared the differential in vitro priming effects of interferon-gamma (IFN-gamma), granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF) on hyphal damage of opportunistic fungi mediated by isolated neutrophils (polymorphonuclear leukocytes, PMNL) and buffy coat cells (polymorphonuclear leukocytes/peripheral blood mononuclear cells, PMNL/PBMC) from healthy donors. IFN-gamma (1000 U/mL) effectively primed both PMNL and PMNL/PBMC for enhanced hyphal damage of Aspergillus fumigatus, Fusarium solani, and Candida albicans. G-CSF (100 ng/mL) increased hyphal damage mediated by both PMNL and PMNL/PBMC against F. solani, and GM-CSF (100 ng/mL) augmented the antifungal activity of PMNL/PBMC against hyphal forms of both F. solani and C. albicans. IFN-gamma may be superior to G-CSF or GM-CSF for enhancing the microbicidal activity of PMNL and PMNL/PBMC against opportunistic fungi.  (+info)

Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. (8/3327)

PURPOSE: To evaluate the feasibility of administering topotecan in combination with paclitaxel and cisplatin without and with granulocyte colony-stimulating factor (G-CSF) support as first-line chemotherapy in women with incompletely resected stage III and stage IV ovarian carcinoma. PATIENTS AND METHODS: Starting doses were paclitaxel 110 mg/m2 administered over 24 hours (day 1), followed by cisplatin 50 mg/m2 over 3 hours (day 2) and topotecan 0.3 mg/m2/d over 30 minutes for 5 consecutive days (days 2 to 6). Treatment was repeated every 3 weeks. After encountering dose-limiting toxicities (DLTs) without G-CSF support, the maximum-tolerated dose was defined as 5 microg/kg of G-CSF subcutaneously starting on day 6. RESULTS: Twenty-one patients received a total of 116 courses at four different dose levels. The DLT was neutropenia. At the first dose level, all six patients experienced grade 4 myelosuppression. G-CSF support permitted further dose escalation of cisplatin and topotecan. Nonhematologic toxicities, primarily fatigue, nausea/vomiting, and neurosensory neuropathy, were observed but were generally mild. Of 15 patients assessable for response, nine had a complete response, four achieved a partial response, and two had stable disease. CONCLUSION: Neutropenia was the DLT of this combination of paclitaxel, cisplatin, and topotecan. The recommended phase II dose is paclitaxel 110 mg/m2 (day 1), followed by cisplatin 75 mg/m2 (day 2) and topotecan 0.3 mg/m2/d (days 2 to 6) with G-CSF support repeated every 3 weeks.  (+info)

TY - JOUR. T1 - Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning. T2 - The effect of postgrafting mycophenolate mofetil dosing. AU - Maris, Michael B.. AU - Sandmaier, Brenda M.. AU - Storer, Barry E.. AU - Maloney, David G.. AU - Shizuru, Judith A.. AU - Agura, Edward. AU - Kliem, Constanze. AU - Pulsipher, Michael. AU - Maziarz, Richard T.. AU - McSweeney, Peter A.. AU - Wade, James. AU - Langston, Amelia A.. AU - Chauncey, Thomas R.. AU - Bruno, Benedetto. AU - Blume, Karl G.. AU - Storb, Rainer. PY - 2006/4/1. Y1 - 2006/4/1. N2 - We previously reported results in 71 patients with advanced hematologic malignancies given HLA-matched unrelated granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell (G-PBMC) grafts after fludarabine 90 mg/m2, 2 Gy of total body irradiation, and postgrafting mycophenolate mofetil (MMF) 15 mg/kg twice daily and cyclosporine 6.25 mg/kg ...
Blood, 2001; 98 (12) doi:. Authors: Zaucha J M, Gooley T, Bensinger W I, Heimfeld S, Chauncey T R Zaucha J M, Gooley T, Bensinger W I, Heimfeld S, Chauncey T R, Zaucha R, Martin P J, Flowers M E, Storek J, Georges G, Storb R, Torok-Storb B et al.(7) Affiliation: Fred Hutchinson Cancer Research Center, United States Abstract: A retrospective analysis of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cell (G-PBMC) products harvested from healthy donors indicates significant variability in both the absolute number and relative proportion of CD34, CD3, and CD14 cells obtained. This report examined whether variations in the cellular composition of G-PBMC products correlated with clinical outcomes after myeloablative allogeneic transplantation. The numbers of CD34, CD3, and CD14 cells infused into 181 human leukocyte antigen (HLA)-identical sibling recipients were analyzed with respect to tempo of engraftment, acute graft-versus-host-disease (GVHD), clinical ...
Study Objective: To determine whether recombinant human granulocyte colony-stimulating factor (G-CSF) is effective in increasing neutrophil counts in patients with hairy cell leukemia and neutropenia.. Design: Open label, phase I/II study of G-CSF, given by daily subcutaneous injection for up to 7 weeks.. Setting: Outpatient oncology clinic of a university medical center.. Patients: A consecutive sample of four patients with hairy cell leukemia complicated by severe neutropenia. Three patients completed the study; one patient was removed after 2 weeks of therapy.. Interventions: Granulocyte colony-stimulating factor was given by daily subcutaneous injection. Each patient began therapy with 1 µg/kg body weight ·d; after 1 week the dose was increased to 3 µg/kg ·d, and 1 week later to 6 µg/ kg ·d. Therapy was continued for 5 to 6 weeks. Patients were taught self-injection, and administered treatment at home.. Measurements and main results: In three patients, an increase in absolute ...
Results. The treatment and placebo groups were of similar gestational age (29 ± 3 vs 31 ± 3 weeks) and birth weight (1376 ± 491 vs 1404 ± 508 g), and had similar Apgar scores and 24-hour Score for Neonatal Acute Physiology scores. The mortality rate was not different between treatment and placebo groups. However, the occurrence of a subsequent nosocomial infection was lower in the rG-CSF recipients (relative risk: .19; 95% confidence interval: .05-.78). rG-CSF treatment did not alter the serum concentrations of the cytokines measured (except for G-CSF). Serum G-CSF levels and blood neutrophil counts were higher in the treatment than in the placebo group 24 hours and 48 hours after dosing. ...
This randomized clinical trial examines the effect of recombinant human granulocyte colony-stimulating factor on peripheral blood leukocyte and lymphocyte cell
TY - JOUR. T1 - Successful Stem Cell Remobilization Using Plerixafor (Mozobil) Plus Granulocyte Colony-Stimulating Factor in Patients with Non-Hodgkin Lymphoma. T2 - Results from the Plerixafor NHL Phase 3 Study Rescue Protocol. AU - Micallef, Ivana N.. AU - Stiff, Patrick J.. AU - DiPersio, John F.. AU - Maziarz, Richard T.. AU - McCarty, John M.. AU - Bridger, Gary. AU - Calandra, Gary. N1 - Funding Information: Financial disclosure: This study was wholly supported by research funding from Genzyme Corporation. The authors thank Sachin Marulkar, Genzyme Corporation, for statistical support and Andrew Dye and Pritesh Gandhi, Genzyme Corporation, for help with the content and coordination of manuscript revisions. P.J.S. and R.T.M. received research funding and honoraria from Genzyme Corporation. I.N.M. received research funding from Genzyme Corporation. J.F.D. received honoraria from Genzyme Corporation. J.M. received honoraria and research funding from Genzyme Corporation and Celgene ...
Abstract. Recombinant human granulocyte colony-stimulating factor (rhG-CSF) enhanced superoxide release and membrane depolarization in parallel in human granulo
TY - JOUR. T1 - Proteolytic enzyme levels are increased during granulocyte colony-stimulating factor-induced hematopoietic stem cell mobilization in human donors but do not predict the number of mobilized stem cells. AU - Van Os, R. AU - Van Schie, MLJ. AU - Willemze, R. AU - Fibbe, WE. PY - 2004/7. Y1 - 2004/7. N2 - Previous studies from our laboratory indicate that functional, mature neutrophils are essential for interleukin-8 (IL-8)-induced stem cell mobilization. To study a possible role of neutrophils in granulocyte colony-stimulating factor (G-CSF) induced hematopoietic mobilization, we assessed the number of circulating CD34(+) cells in healthy allogeneic stem cell donors on days 3, 4, and 5 of mobilization for comparison with the number of peripheral blood neutrophils and the plasma levels of IL-8, Flt3 ligand (FL), matrix metalloproteinase-9 (MMP-9), and human neutrophil elastase (HNE). Thirty-seven of 45 donors required 1 day of apheresis to obtain 5 x 10(6) CD34(+)/kg recipient body ...
Bioassay of Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) for Neutropenia Treatment in Male Sprague Dawley Rats
Dragon Pharmaceutical announced to in-license the exclusive right to commercialize its Recombinant Human Granulocyte Colony Stimulating Factor.
TY - JOUR. T1 - COMPLETE REMISSION IN ACUTE MYELOID LEUKAEMIA AFTER TREATMENT WITH RECOMBINANT HUMAN GRANULOCYTE COLONY‐STIMULATING FACTOR AND HIGH DOSE INTRAVENOUS METHYLPREDNISOLONE. AU - Sugawara, Tomohiro. AU - Sato, Akiyoshi. AU - Shishido, Tomoaki. AU - Okuda, Mitsutaka. AU - Kameoka, Junichi. AU - Meguro, Kuniaki. AU - Endo, Kazuyasu. AU - Yoshinaga, Kaoru. PY - 1991/4. Y1 - 1991/4. UR - http://www.scopus.com/inward/record.url?scp=0025763424&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0025763424&partnerID=8YFLogxK. U2 - 10.1111/j.1365-2141.1991.tb08627.x. DO - 10.1111/j.1365-2141.1991.tb08627.x. M3 - Article. C2 - 1709041. AN - SCOPUS:0025763424. VL - 77. SP - 561. EP - 562. JO - British Journal of Haematology. JF - British Journal of Haematology. SN - 0007-1048. IS - 4. ER - ...
Importance: Currently the gold standard treatment for ambulant patients is corticosteroids. Granulocyte colony-stimulating factor (G-CSF) has been reported to exert the proliferation of satellite cells, the regulation of myoblast proliferation, and the differentiation and promotion of muscle regeneration and repair.. Objectives To evaluate the safety and efficacy of G-CSF in children and adolescents with muscular dystrophies Duchenne muscular dystrophy, Becker muscular dystrophy , Fascioscapulohumeral dystrophy.. Design, Setting, and Participants: Patients aged 5-15 with diagnosed muscular dystrophies will be included in an open study. Patients wheelchair-bound and and mobile and self-independent can participate in the study. Patients also treated with steroids can participate in this study. Clinical examination and physiotherapeutic and laboratory tests will be perform. G-CSF (5mcg/kg/body/d) is given subcutaneously for five consecutive days during the 1st, 2nd, 3rd. 6th and 12th months. Blood ...
Importance: Currently the gold standard treatment for ambulant patients is corticosteroids. Granulocyte colony-stimulating factor (G-CSF) has been reported to exert the proliferation of satellite cells, the regulation of myoblast proliferation, and the differentiation and promotion of muscle regeneration and repair.. Objectives To evaluate the safety and efficacy of G-CSF in children and adolescents with muscular dystrophies Duchenne muscular dystrophy, Becker muscular dystrophy , Fascioscapulohumeral dystrophy.. Design, Setting, and Participants: Patients aged 5-15 with diagnosed muscular dystrophies will be included in an open study. Patients wheelchair-bound and and mobile and self-independent can participate in the study. Patients also treated with steroids can participate in this study. Clinical examination and physiotherapeutic and laboratory tests will be perform. G-CSF (5mcg/kg/body/d) is given subcutaneously for five consecutive days during the 1st, 2nd, 3rd. 6th and 12th months. Blood ...
BACKGROUND AND OBJECTIVE: Anemia leading to transfusion is probably the most important problem in patients with myelodysplastic syndromes (MDS). Human recombinant erythropoietin (rHuEpo) and granulocyte colony-stimulating factor (G-CSF) have been used to treat patients with anemia of MDS, but fewer than 50% respond. The aim of this work was to evaluate the benefit of rHuEpo +/- G-CSF treatment and to isolate the response predictive variables in a group of selected patients with MDS. DESIGN AND METHODS: A non-randomized multicenter trial was carried out in 32 patients with MDS. The inclusion criteria were age ,= 18 years, refractory anemia (RA) or refractory anemia with ringed sideroblasts, Hb ,= 100 g/L or receiving transfusions and serum erythropoietin ,= 250 U/L. These patients were treated with subcutaneous rHuEpo (300 U/kg) three times a week for 8 weeks. In the case of partial response (PR) or no response (NR) subcutaneosly administered G-CSF (1 microg/kg) three times a week was added to ...
Title: Granulocyte Colony-Stimulating Factor (G-CSF) in the Mechanism of Human Ovulation and its Clinical Usefulness. VOLUME: 15 ISSUE: 6. Author(s):T. Waseda, H. Tomizawa, R. Fujii, S. Makinoda and N. Hirosaki. Affiliation:Department of Obstetrics and Gynecology,Kanazawa Medical University, Uchinada, 920-0293 Japan.. Keywords:human chorionic gonadotropin (hCG), clomiphene, luteinized unruptured follicle (LUF), cytokine, granulocyte, leukocyte, ovulation, Granulocyte colony-stimulating factor (G-CSF). Abstract: In 1980, Espey proposed a famous hypothesis that mammalian ovulation is comparable to an inflammatory reaction and many researches have proved the validity of his hypothesis in the last three decades. For example, interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF) and other inflammatory cytokines presence was proven in the preovulatory follicle. Since granulocyte is the major ...
BACKGROUND: AVI-014 is an egg white-derived, recombinant, human granulocyte colony-stimulating factor (G-CSF). This healthy volunteer study is the first human investigation of AVI-014. METHODS: 24 male and female subjects received a single subcutaneous injection of AVI-014 at 4 or 8 mcg/kg. 16 control subjects received 4 or 8 mcg/kg of filgrastim (Neupogen, Amgen) in a partially blinded, parallel fashion. RESULTS: The Geometric Mean Ratio (GMR) (90% CI) of 4 mcg/kg AVI-014/filgrastim AUC(0-72 hr) was 1.00 (0.76, 1.31) and Cmax was 0.86 (0.66, 1.13). At the 8 mcg/kg dose, the AUC(0-72) GMR was 0.89 (0.69, 1.14) and Cmax was 0.76 (0.58, 0.98). A priori pharmacokinetic bioequivalence was defined as the 90% CI of the GMR bounded by 0.8-1.25. Both the white blood cell and absolute neutrophil count area under the % increase curve AUC(0-9 days) and Cmax (maximal % increase from baseline)GMR at 4 and 8 mcg/kg fell within the 0.5-2.0 a priori bound set for pharmacodynamic bioequivalence. The CD 34+ % increase
Fingerprint Dive into the research topics of Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis. Together they form a unique fingerprint. ...
The mortality rate at eight weeks was similar in the lenograstim and placebo groups (23 and 27 percent, respectively; P = 0.60), as was the incidence of severe infections. The median duration of neutropenia (absolute neutrophil count , or = 1000 per cubic millimeter) was shorter in the lenograstim group (21 days, as compared with 27 days in the placebo group; P , 0.001). Eight percent of the patients in both groups had regrowth of AML cells. The rate of complete remission was significantly higher in the lenograstim group (70 percent, as compared with 47 percent in the placebo group; P = 0.002). Overall survival, however, was similar in the two groups (P = 0.76). Conclusions: ...
TY - JOUR. T1 - Granulocyte colony-stimulating factor (G-GSF) prevents dose-limiting neutropenia in lymphoma patients receiving standard dose chemotherapy. AU - Dotti, G.. AU - Carlo Stella, C.. AU - Mangoni, L.. AU - Cottafavi, L.. AU - Caramatti, C.. AU - Almici, C.. AU - Rizzoli, V.. PY - 1995. Y1 - 1995. N2 - In this study, nine patients with non-Hodgkins lymphoma (n=6) and Hodgkins disease (n=3) receiving different cytotoxic chemotherapy regimens were given granulocyte colony-stimulating factor (C-CSF) (5 μg/kg/day) from 48 hours after the end of chemotherapy to 48 hours before the next chemotherapy administration. The decrease in mean absolute neutrophil counts (ANC) and in mean platelet (Plt) counts was not significant when pre-therapy counts were compared with posttherapy ones (p ,0.375 and p , 0.4, respectively). The mean actual dose intensity was 92% (range 68-100%). G-CSF treatment after chemotherapy reduces neutropenia and permits administration of the full chemotherapy program. A ...
TY - JOUR. T1 - A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor. AU - Schiller, J. H.. AU - Storer, B.. AU - Tutsch, K.. AU - Arzoomanian, R.. AU - Alberti, D.. AU - Feierabend, C.. AU - Spriggs, D.. PY - 1994/11/3. Y1 - 1994/11/3. N2 - Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), a novel antitubulin agent derived from the bark of the Pacific yew tree, may be one of the most active single agents in our chemotherapy armamentarium. Concern over acute hypersensitivity reactions has resulted in an administration schedule consisting of a 24-hour infusion. We conducted a phase I trial of a 3-hour infusion of paclitaxel to determine whether a 3-hour infusion could be administered with relative safety, and to identify the maximal tolerated dose with and without granulocyte colony-stimulating factor (G-CSF) support. Thirty-five patients with advanced, untreatable malignancies received a 3- hour infusion of paclitaxel once ...
Alzheimers disease (AD) is widely recognized as a serious public health problem and heavy financial burden. Currently, there is no treatment that can delay or stop the progressive brain damage in AD. Recently, we demonstrated that stem cell factor (SCF) in combination with granulocyte colony-stimulating factor (G-CSF) (SCF+G-CSF) has therapeutic effects on chronic stroke. The purpose of the present study is to determine whether SCF+G-CSF can reduce the burden of β-amyloid deposits in a mouse model of AD. APP/PS1 transgenic mice were used as the model of AD. To track bone marrow-derived cells in the brain, the bone marrow of the APP/PS1 mice was replaced with the bone marrow from mice expressing green fluorescent protein (GFP). Six weeks after bone marrow transplantation, mice were randomly divided into a saline control group and a SCF+G-CSF-treated group. SCF in combination with G-CSF was administered subcutaneously for 12 days. Circulating bone marrow stem cells (CD117+ cells) were quantified 1 day
OBJECTIVES: To estimate the cord blood levels of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in preterm infants and to study the relationship of these levels to pregnancy-induced hypertension (PIH) and absolute neutrophil counts.. STUDY DESIGN: G-CSF and GM-CSF levels in the cord blood of preterm neonates (n = 74) either with or without maternal PIH were estimated by enzyme-linked immunosorbent assay.. RESULTS: Infants in the PIH group had lower white blood cell, absolute neutrophil, absolute lymphocyte, and monocyte counts. The levels of G-CSF in cord blood were significantly lower in infants whose mothers had PIH (P =.04) and in infants with neutropenia (P =. 01). G-CSF levels were positively correlated with both absolute neutrophil count (P =.02) and total white blood cell count (P =.01). GM-CSF was undetectable in all subjects. According to logistic regression with neutropenia as the dependent variable, only maternal PIH (P ...
Our preliminary results suggest the existence of quantitative and qualitative differences in immune cells and type1 and type2 cytokines between granulocyte colony-stimulating factor (G-CSF) primed bone marrow (G-BM) and G-CSF-mobilized peripheral blood grafts (G-PB). Our findings suggest that lower T-cell hyporesponsiveness and easier polarization of T cells from Th1 to Th2 are found in G-BM. ...
Abstract. Congenital neutropenia (Kostmanns syndrome [KS]) is an autosomal recessive syndrome that is characterized by profound neutropenia, resulting in major
Product Name: Mouse mAb anti- human Granulocyte Colony Stimulating Factor Receptor (G-CSFR), Clone S-1268Collection: AntibodySub Category: Monoclonal
Bone marrow mononuclear cell (BMMC) transplantation is a promising therapy for cerebral ischemia; however, little is known if its therapeutic efficacy may be improved by co-administration of potential modulatory factors in vivo. To explore this possibility, the present study examined the effect of BMMCs and G-CSF on cell proliferation, early neuronal development and neurological function recovery in experimental cerebral ischemia relative to controls that received neither treatment. Ischemia/infarct area was significantly reduced in BMMCs+G-CSF group relative to animal groups treated with BMMCs only, G-CSF only or saline. Transplanted BMMCs were found to colocalize with the proliferative cell nuclear antigen (PCNA) and the immature neuronal marker doublecortin (DCX). The BMMCs+G-CSF group showed increased numerical density of cells expressing PCNA and DCX, improved performance in adhesive sticker removal test and reduced neurological function severity scores relative to other groups in a time-dependent
Bone marrow mononuclear cell (BMMC) transplantation is a promising therapy for cerebral ischemia; however, little is known if its therapeutic efficacy may be improved by co-administration of potential modulatory factors in vivo. To explore this possibility, the present study examined the effect of BMMCs and G-CSF on cell proliferation, early neuronal development and neurological function recovery in experimental cerebral ischemia relative to controls that received neither treatment. Ischemia/infarct area was significantly reduced in BMMCs+G-CSF group relative to animal groups treated with BMMCs only, G-CSF only or saline. Transplanted BMMCs were found to colocalize with the proliferative cell nuclear antigen (PCNA) and the immature neuronal marker doublecortin (DCX). The BMMCs+G-CSF group showed increased numerical density of cells expressing PCNA and DCX, improved performance in adhesive sticker removal test and reduced neurological function severity scores relative to other groups in a time-dependent
TY - JOUR. T1 - Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxoruhicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer. AU - Ardizzoni, A.. AU - Pennucci, M. C.. AU - Danova, M.. AU - Viscoli, C.. AU - Mariani, G. L.. AU - Giorgi, G.. AU - Venturini, M.. AU - Mereu, C.. AU - Scolaro, T.. AU - Rosso, R.. PY - 1996. Y1 - 1996. N2 - A phase I study was designed to assess whether dose intensity of an accelerated cyclophosphamide- doxorubicin- etoposide (CDE) regimen plus granulocyte colony-stimulating factor (G-CSF) could be increased further, in an outpatient setting, by escalating the dose of each single drug of the regimen. Patients with previously untreated small-cell lung cancer (SCLC) received escalating doses of cyclophosphamide (C) 1100-1300 mg m-2 intravenously (i.v.) on day I, doxorubicin (D) 50-60 mg m-2 i.v. on day 1, etoposide (E) 110-130 mg m-2 i.v. ...
Gentaur molecular products has all kinds of products like :search , Prospecbio \ Mouse Anti Human Granulocyte Colony Stimulating Factor Biotin \ ANT-240 for more molecular products just contact us
The recombinant human G-CSF (rhG-CSF) synthesised in an E. coli expression system is called filgrastim. The structure of filgrastim differs slightly from the structure of the natural glycoprotein. Most published studies have used filgrastim. Filgrastim was first marketed by Amgen with the brand name Neupogen. Several bio-generic versions are now also available in markets such as Europe and Australia. Filgrastim (Neupogen) and PEG-filgrastim (Neulasta) are two commercially available forms of rhG-CSF. The PEG (polyethylene glycol) form has a much longer half-life, reducing the necessity of daily injections. Another form of rhG-CSF called lenograstim is synthesised in Chinese Hamster Ovary cells (CHO cells). As this is a mammalian cell expression system, lenograstim is indistinguishable from the 174-amino acid natural human G-CSF. No clinical or therapeutic consequences of the differences between filgrastim and lenograstim have yet been identified, but there are no formal comparative studies. ...
Granulocyte colony-stimulating factor (G-CSF) is the major regulator of granulopoiesis and acts through binding to its specific receptor (G-CSF-R) on neutrophilic granulocytes. Previous studies of signaling from the 4 G-CSF-R cytoplasmic tyrosine residues used model cell lines that may have idiosyncratic, nonphysiological responses. This study aimed to identify specific signals transmitted by the receptor tyrosine residues in primary myeloid cells. To bypass the presence of endogenous G-CSF-R, a chimeric receptor containing the extracellular domain of the epidermal growth factor receptor in place of the entire extracellular domain of the G-CSF-R was used. A series of chimeric receptors containing tyrosine mutations to phenylalanine, either individually or collectively, was constructed and expressed in primary bone marrow cells from G-CSF-deficient mice. Proliferation and differentiation responses of receptor-expressing bone marrow cells stimulated by epidermal growth factor were measured. An ...
The proliferative responsiveness of granulocyte colony-stimulating factor (G-CSF)-mobilized blood was studied in uni-directional mixed leukocyte cultures. Unfractionated mononuclear cells from mobilized blood obtained by leukapheresis at day 4 after initiation of G-CSF (G-PBMC) were hyporesponsive (31.5% +/- 9.2% response, P = .003) compared to mononuclear cells obtained from the peripheral blood before administration of G-CSF (preG-PBMC). There was great variability among donors when purified preG- and G-CD4 cells were compared. In eight of 10 donors, G-CD4 cells were equally responsive or moderately hyporesponsive; in two of 10 donors, G-CD4 cells were more strikingly hyporesponsive. CD14 cells derived from leukapheresis products (G-CD14 cells) suppressed alloantigen-induced proliferation by 48.6% +/- 7.5% when added to preG-PBMC or preG-CD4 cells at responder-CD14 ratios of 2:1 (P , .001). Suppression was evident (14.4% +/- 5.0%) even at responder-CD14 ratios of 8:1 and was largely ...
SkyePharma is developing a formulation of granulocyte colony-stimulating factor (GCSF) for the prevention and treatment of chemotherapy-induced neutropenia.The
Individuals with severe forms of congenital neutropenia suffer from recurrent infections. The therapeutic use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) to increase the neutrophil count is associated with fewer infections and an improved quality of life. However, the long-term effects of this new therapy are largely unknown. In particular, it is unclear if myeloid leukemia, a known complication of some forms of congenital neutropenia, will occur with increased frequency among patients who receive long-term treatment with hematopoietic growth factors. We report 13 patients with congenital disorders of myelopoiesis who developed leukemic transformation with either myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) and 1 who acquired a clonal cytogenetic abnormality without evidence of MDS or AML while receiving rhG-CSF. The bone marrows of 10 patients showed monosomy 7 and 5 had activating RAS mutations. These abnormalities were not detected in ...
Background: Recent studies have shown that bone marrow mesenchymal stem cells (BMSCs) have a putative ability to promote neurogenesis and produce behavioral and functional improvement. Our previous study demonstrated that co-treatment of granulocyte colony-stimulating factor (G-CSF) and BMSCs have beneficial effects on Parkinson's models. The main purpose of this research was ...
Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkins lymphoma: results of a phase II study.
1. Granulocyte colony stimulating factor (G-CSF) is reported to have a beneficial effect on cardiac dysfunction in postinfarction and doxorubicin-induced cardiomyopathy. Thus, the aim of the present study was to investigate the effects of G-CSF on cardiac remodelling in angiotensin (Ang) II-induced hypertrophy. 2. Four groups of mice were investigated. The first group served as a control group. The second group was injected with recombinant human G-CSF (10 microg/kg per day, s.c.) on the first 5 days of each week and treatment was continued for 4 weeks. An osmotic minipump was implanted subcutaneously into each mouse in the third group so that pressor doses of AngII (2.88 mg/kg per day) or saline could be administered over a period of 4 weeks. The fourth group was infused with AngII (2.88 mg/kg per day) and injected with G-CSF (10 microg/kg per day, s.c.) for 4 weeks. 3. Angiotensin II treatment significantly elevated blood pressure and caused cardiac hypertrophy and fibrosis in mice. Treatment ...
Active Recombinant human G-CSF protein is a HEK 293 Protein fragment 31 to 204 aa range, | 95% purity, | 1.000 Eu/µg endotoxin level and validated in FuncS, SDS-PAGE. The bio-activity was determined …
Buy our Recombinant human G-CSF protein. Ab9692 is an active full length protein produced in Escherichia coli and has been validated in FuncS, SDS-PAGE. Abcam…
The treatment of elderly patients with an aggressive non-Hodgkins lymphoma has gradually changed over the last decades. The first publications concerning elderly patients with lymphoma emphasized the increased toxicity and poor outcome of this patient group.(1-3) The aim of many subsequent studies has been to decrease toxicity.(4-6) Most of these studies however reported decreased response rates and deterioration of survival if age adapted therapy was used. It also became evident that doxorubicin proved to be a toxic, but essential drug in any regimen prescribed with a curative intention.(7-9) The development of recombinant granulocyte colony-stimulating factor (G-CSF) raised expectations that this growth factor could improve the results of therapy because it would become possible to maintain the dose-intensity of the chemotherapy regimen by inducing rapid hematopoietic recovery.(10) Moreover, a shorter duration of the neutropenic phase could probably reduce the incidence of neutropenic fever, ...
CSPC Pharma is developing pegfilgrastim (PEG-rhG-CSF), a pegylated recombinant granulocyte colony-stimulating factor receptor agonist, for the prevention of
Dive into the research topics of Extracellular signal-regulated kinase 2 mediates the expression of granulocyte colony-stimulating factor in invasive cancer cells. Together they form a unique fingerprint. ...
Compliance with orders for granulocyte colony-stimulating factors (G-CSFs) is suboptimal, and inadequate prophylaxis was directly tied to hospital admissions, according to results of a recent clinical trial from the University of Pennsylvania Health System.
Cytokine regulation of prethymic T-lymphoid progenitor-cell proliferation and/or differentiation has not been well-defined, although much is known of cytokine regulation of hemopoietic stem- and progenitor-cell development. Here we use a recently identified hemopoietic growth factor, stem-cell factor (SCF) (a form of the c-kit ligand), and a transplant model of thymocyte regeneration to assess the effect of SCF on the in vivo generation of prethymic, thymocyte progenitor-cell activity. We show that recombinant rat SCF (rrSCF164) administered to weanling rats selectively induces an increase in thymocyte progenitor activity in the spleens of treated rats as compared to rats treated with vehicle, polyethylene glycol (PEG)-conjugated rat albumin, or recombinant human granulocyte colony-stimulating factor (rhG-CSF). These data demonstrate that administration of SCF in vivo affects extrathymic-origin thymocyte regenerating cells and may influence, directly or indirectly, early prethymic stages of T-cell
In this study we aimed to evaluate the relationship between serum granulocyte colony stimulating factor (G-CSF) levels and absolute neutrophil counts (ANC) in infants of preeclamptic mothers. ...
cost. 2 Prophylactic use of recombinant human granulocyte colony-stimulating factors (G-CSFs), such as filgrastim or pegfilgrastim, can significantly reduce FN risk and FN-related costs. 3 - 5 The risk of developing FN depends on patient and disease. ...
Introduction: Naturally occurring antibodies (auto-Abs) recognizing human granulocyte-colony stimulating factor were detected with high frequency in serum samples obtained from umbilical cord blood of newborns (12 of 65 samples screened) and maternal peripheral blood serum samples from women at the end of gestation (seven of 56 cases tested). The aim of this paper was to demonstrate that auto-Abs anti-G-CSF revealed in the blood of newborns were produced during foetal life. Materials and methods: Mononuclear cells from cord blood samples of different newborns containing high titer anti-G-CSF Abs were infected with Epstein-Barr virus in vitro, and EBV-immortalized B-cell lines were isolated and characterized for specific anti-G-CSF Ab production. Results: Six different, unrelated cell lines of male origin which showed the presence of EBNA-2 antigen in the nucleus, displayed a B-cell phenotype (CD30+, CD5-, CD10-, HLA-DR+, CD19+, CD20+, CD23+, CD38+, CD25+), coexpressed low intensity sIgM and ...
The results of the present study demonstrate that G-CSF is neuroprotective in vitro (nearly complete protection) and displays a significant (47%) infarct-reducing effect after stroke and after intravenous administration. Neurons in the periphery of the infarction but also on the contralateral side exhibited specific binding of G-CSFR antiserum, indicative of a G-CSFR. Because the presence of G-CSFR on neurons is novel, we verified this finding by Western blot and RT-PCR. Furthermore, STAT3 expression was significantly increased in neurons of the penumbra in G-CSF-treated animals compared with control animals, suggesting an increased sensitivity to G-CSF. There was no effect on CBF as measured by LDF when both groups were compared. There were no significant differences in physiological parameters or in weight decline between both groups during the experiment. Mortality rate was significantly improved in animals treated with G-CSF compared with control animals. Neutrophilic blood count was ...
Human granulocyte colony stimulating factor (G-CSF) and macrophage colony stimulating factor (M-CSF) were administered intravenously to rats, and their effects on neutrophils and monocytes were...
Looking for online definition of granulocyte colony-stimulating factor in the Medical Dictionary? granulocyte colony-stimulating factor explanation free. What is granulocyte colony-stimulating factor? Meaning of granulocyte colony-stimulating factor medical term. What does granulocyte colony-stimulating factor mean?
Severe chronic neutropenia (SCN) is defined as an absolute neutrophil (ANC) of less than 0.5 x 10(9)/L, lasting for months or years. Congenital, cyclic, and idiopathic neutropenia are principal categories of SCN. Since 1994, the Severe Chronic Neutropenia International Registry (SCNIR) has collected data to monitor the clinical course, treatments, and disease outcomes for SCN patients. This report summarizes data for 853 patients, almost all treated with daily or alternate-day recombinant human granulocyte colony-stimulating factor (G-CSF or Filgrastim). G-CSF treatment increased the ANC overall from 0.34 x 10(9)/L +/- 0.018 pre-treatment to 3.70 x 10(9)/L +/- 0.18 during the first year of treatment. For most patients, the responses were durable with patients remaining on the same dose of G-CSF for many years. Long-term hematological observations showed stable mean leukocyte and neutrophil counts and gradually increasing hemoglobin levels. Thrombocytopenia developed in 4% of patients. As of ...
TY - CONF. T1 - Extractables and Leachables from Filter Material and their Effect on Human Granulocyte Colony-Stimulating Factor (hG-CSF). AU - Wahl, Verena. AU - Mohr, Stefan. AU - Wieser, Juliana. AU - Khinast, Johannes. AU - Paudel, Amrit. PY - 2015/11/11. Y1 - 2015/11/11. M3 - (Altdaten) Vortrag oder Präsentation. ER - ...
BACKGROUND AND OBJECTIVES: There is wide interindividual variation in progenitor cell mobilization. The present study was aimed to analyze steady state hematopoiesis in healthy donors and its influence on hematopoietic progenitor cell (HPC) mobilization. DESIGN AND METHODS: Bone marrow (BM) was aspirated from 72 healthy donors prior to administration of recombinant human granulocyte colony-stimulating factor (G-CSF). Analyses of CD34+ cells and semisolid cultures as well as long-term cultures were performed from BM or leukapheresis products. RESULTS: Male donors showed a higher number of BFU-E (p=0.007) and committed progenitors (p=0.05), a better stromal layer (p=0.02), and higher long-term bone marrow culture (LT-BMC) counts (p,0.05) when compared to those in female donors. When correlating the culture pattern of the BM with the data from the leukapheresis products, we observed that the number of the immature progenitors in BM correlated significantly with both the number of CD34 + cells and ...
TY - JOUR. T1 - Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor. T2 - Association with donor characteristics. AU - Joshi, Shantaram S.. AU - Lynch, James C.. AU - Pavletic, Steve Z.. AU - Tarantolo, Stefano R.. AU - Pirruccello, Samuel J.. AU - Kessinger, Anne. AU - Bishop, Michael R.. N1 - Copyright: Copyright 2012 Elsevier B.V., All rights reserved.. PY - 2001/9/15. Y1 - 2001/9/15. N2 - In this study, mononuclear cells (MNCs) from granulocyte colony-stimulating factor (G-CSF)-mobilized blood stem cell (BSC) harvests from 104 healthy donors were analyzed for their immunological functions and compared with MNCs from 28 steady-state nonmobilized donors. The relationships between donor characteristics (age, gender, weight, and HLA type) and immune functions of the harvests were also analyzed. There was a significant (P , .01) decrease in natural killer and lymphokine-activated killer (LAK) cell-mediated cytotoxicity for G-CSF-mobilized ...
TY - JOUR. T1 - Treating chemotherapy induced agranulocytosis with granulocyte colony-stimulating factors in a patient on clozapine. AU - Kolli, Venkata. AU - Denton, Kevin. AU - Borra, Dileep. AU - Pulluri, Madhuri. AU - Sharma, Ashish. PY - 2013/7/1. Y1 - 2013/7/1. N2 - Background Clozapine is reserved for overcoming treatment resistance in schizophrenia. Malignancy is common in schizophrenia; however, there is limited evidence available on continuing clozapine with chemotherapy, with both having hematological adverse effects. Objective To report a case on the use of granulocyte colony-stimulating factor (G-CSF) in conjunction with clozapine and chemotherapy. Methods We searched PubMed for any available information on the use of granulocyte G-CSF with clozapine and chemotherapy. We report the case of a patient with schizophrenia who developed B-cell lymphoma and was treated with chemotherapy consisting of CHOP regimen, rituximab, and methotrexate. He was continued on clozapine and G-CSF. ...
BACKGROUND: The use of granulocyte colony-stimulating factor (G-CSF) can enable dose intensification of chemotherapy in small-cell lung cancer (SCLC). However, given its acquisition cost, it is important to assess its cost effectiveness within a resource-constrained health service. OBJECTIVE: To assess the cost effectiveness, from the UK NHS perspective, of G-CSF given in addition to doxorubicin, cyclophosphamide and etoposide (ACE) versus ACE alone in the management of SCLC. METHODS: Using data from a UK Medical Research Council trial (LU19) to assess chemotherapy dose intensification in patients with previously untreated SCLC of any disease extent, a retrospective cost-effectiveness analysis was undertaken. Resource use data, including hospitalisations and non-protocol cancer treatments, were collected during the first 6-month treatment phase of the trial. Mean costs ( pound, 2003 values) of managing patients in the two arms of the trial were calculated. Mean survival duration was calculated ...
Clozapine-Associated Agranulocytosis Treatment With Granulocyte Colony-Stimulating Factor/Granulocyte-Macrophage Colony-Stimulating Factor: A Systematic Review.
Exposure to a moderate to high dose of ionizing radiation (IR) not only causes acute radiation syndrome but also induces long-term (LT) bone marrow (BM) injury. The latter effect of IR is primarily attributed to the induction of hematopoietic stem cell (HSC) senescence. Granulocyte colony-stimulating factor (G-CSF) is the only treatment recommended to be given to radiation victims soon after IR. However, clinical studies have shown that G-CSF used to treat the leukopenia induced by radiotherapy or chemotherapy in patients can cause sustained low white blood cell counts in peripheral blood. It has been suggested that this adverse effect is caused by HSC and hematopoietic progenitor cell (HPC) proliferation and differentiation stimulated by G-CSF, which impairs HSC self-renewal and may exhaust the BM capacity to exacerbate IR-induced LT-BM injury. C57BL/6 mice were exposed to 4 Gy γ-rays of total body irradiation (TBI) at a dose-rate of 1.08 Gy per minute, and the mice were treated with G-CSF (1 μg/each
The European branch of the SCNIR is actively cooperating with pediatricians and hematologists all over Europe. Since December 2001 the activities of the European neutropenia network are being supported by a grant of the European Commission in the program Rare Diseases. Thanks to the funding of the EU Commission, an Internet-accessible database system was acquired that enables all centers participating in the SCNIR to get the most pertinent information on severe chronic neutropenia directly via the Internet.. The SCNIR collects both, general and specific clinical information, e.g. on malignant transformation, bone marrow transplantation and outcome etc., on patients with severe chronic neutropenia. All information arising from the database of the European Branch of the Severe Chronic Neutropenia International Registry is disseminated among the members of this network in order to provide an update of the professional skills of the European network partners, which in turn is passed on to other ...
TY - JOUR. T1 - Human CD34+ bone marrow cells regulate stromal production of interleukin-6 and granulocyte colony-stimulating factor and increase the colony-stimulating activity of stroma. AU - Gupta, Pankaj. AU - Blazar, Bruce R. AU - Gupta, Kalpna. AU - Verfaillie, Catherine M.. N1 - Copyright: Copyright 2020 Elsevier B.V., All rights reserved.. PY - 1998/5/15. Y1 - 1998/5/15. N2 - Cytokines produced by stromal cells induce the proliferation and differentiation of hematopoietic cells in the marrow microenvironment. We hypothesized that cross-talk between hematopoietic cells at different stages of differentiation and stromal cells influences stromal cytokine production and is responsible for maintaining steady-state hematopoiesis and responding to stress situations. We show that coculture of primitive CD34+ cells in contact with or separated by a transwell membrane from irradiated human bone marrow stromal layers induces a fourfold to fivefold increase in interleukin- 6 (IL-6) and granulocyte ...
To date, no reliable methods have proven effective for treating spinal cord injury (SCI). Even systemic administration of methylprednisolone (MP) remains controversial. We previously reported that intrathecal (i.t.) administration of granulocyte colony-stimulating factor (G-CSF) improves outcome after experimental spinal cord ischemic insults in rats. The present study aimed to examine the neuroprotective efficacy of i.t. G-CSF or MP in rats with SCI. Female rats were subjected to spinal cord contusion injury at T10 using NYU impactor. We i.t. administered G-CSF (10 μg) or MP (one bolus of 100 μg, followed by 18 μg/h infusion for 23 h) immediately after SCI. Both G-CSF and MP significantly improved the rats motor function after SCI. Immunofluorescence staining revealed suppressed expression of transforming growth factor-beta 1 (TGF-β1), chondroitin sulfate proteoglycans (neurocan and phosphacan), OX-42 and tumor necrosis factor alpha after i.t. G-CSF, but not MP, in rats with SCI. In ...
MAIN RESULTS: We identified four RCTs fitting the inclusion criteria. However, two of these closed prematurely due to low recruitment and did not report results. The remaining two trials evaluated 600 participants with multiple myeloma or non-Hodgkin lymphoma. In both studies the experimental group received G-CSF plus plerixafor and the control group received G-CSF plus placebo.The meta-analysis showed no evidence for differences between plerixafor and placebo group regarding mortality at 12 months (600 participants; risk ratio (RR) 1.00, 95% confidence interval (CI) 0.59 to 1.69; P = 1.00; moderate-quality evidence) and adverse events during stem cell mobilisation and collection (593 participants; RR 1.02, 95% CI 0.99 to 1.06; P = 0.19; high-quality evidence).Regarding the outcome successful stem cell collection, the meta-analysis showed an advantage for those participants randomised to the plerixafor group (600 participants; RR 2.42, 95% CI 1.98 to 2.96; P , 0.00001; high-quality evidence).As ...
Non-glycosylated, recombinant human granulocyte colony-stimulating factor (rhG-CSF), produced by Escherichia coli(filgrastim, leukostim) is widely used to treat a number of serious human diseases...
Generon, a Shanghai innovative biopharma, has forged a Special Protocol Assessment with the US FDA for the design of a second Phase III trial of its lead candidate. Gereron believes F-627 (benegrastim), a second-generation recombinant human granulocyte colony-stimulating factor dimer, has best-in-class potential to treat chemotherapy-induced neutropenia. The company is also testing a first-in-class recombinant human interleukin-22 as a treatment for graft-vs-host disease and acute alcoholic hepatitis.. Source: China Biotoday. ...
The European Medicines Agency (EMA) has accepted an application to review Sandozs biosimilar to Amgens EU-licensed Neulasta (pegfilgrastim), a recombinant human granulocyte colony-stimulating factor, Sandoz parent Novartis said on Thursday.
Neutropenia is an absolute decrease in the number of circulating neutrophils in the blood which results in susceptibility to severe pyogenic infections. Various oral findings such as periodontitis, alveolar bone loss and ulceration may be seen in neutropenic patients. A case is presented of a 6 year old girl with chronic, probably congenital, severe neutropenia with frequent respiratory tract infections, recurrent oral ulcerations and significant periodontal breakdown resembling prepubertal periodontitis. She was given granulocyte-colony stimulating factor (G-CSF) treatment which resulted in an increase in granulocyte count within two weeks and resolution of the neutropenic ulceration. It is suggested that G-CSF together with dental care regimens is a promising treatment model in chronic severe neutropenia cases presenting with oral manifestations. ...
Severe Chronic Neutropenia International Registry, info about Conditions and Diseases: Blood Disorders: Neutropenia: Severe Chronic Neutropenia International Registry
This new market research report forecasts on Granulocyte Colony Stimulating Factor Drug Market providing complete market figures, consisting market size and estimation by Granulocyte Colony Stimulating Factor Drug Market application and products depending upon geographical location for the forecasting period 2017 to 2025. Further, the Granulocyte Colony Stimulating Factor Drug Market research report study also encompasses complete industry background, with Granulocyte Colony Stimulating Factor Drug Market drivers, competitive market dynamics, market restraints, market growth opportunities, industry challenges and critical success factors (CSFs). The Granulocyte Colony Stimulating Factor Drug Market research report examines top industry competitors, offering organization market share analysis and detailed outlines of these firms, with product benchmarking.. Browse Full Report Visit - http://bit.ly/2vrsZW5. Reasons to Buy This Report :. ...
Interleukin-3; Burst-Promoting Factor, Erythrocyte; Colony-Stimulating Factor, Mast-Cell; Colony-Stimulating Factor, Multipotential; Colony-Stimulating Factor 2 Alpha; Erythrocyte Burst-Promoting Factor; Multipotential Colony-Stimulating Factor; P-Cell Stimulating Factor; IL-3; Mast-Cell Colony-Stimulating Factor. On-line free medical diagnosis assistant. Ranked list of possible diseases from either several symptoms or a full patient history. A similarity measure between symptoms and diseases is provided.
Cocaine addiction is characterized by aberrant plasticity of the mesolimbic dopamine circuit, leading to dysregulation of motivation to seek and take drug. Despite the significant toll that cocaine use disorder exacts on society, there are currently no available pharmacotherapies. We have recently identified granulocyte-colony stimulating factor (G-CSF) as a soluble cytokine that alters the behavioral response to cocaine and which increases dopamine release from the ventral tegmental area (VTA). Despite these known effects on behavior and neurophysiology, the molecular mechanisms by which G-CSF affects brain function are unclear. In this study mice were treated with repeated injections of G-CSF, cocaine or a combination and changes in protein expression in the VTA were examined using an unbiased proteomics approach. Repeated G-CSF treatment resulted in alterations in multiple signaling pathways related to synaptic plasticity and neuronal morphology. While the treatment groups had marked overlap in their
This randomised controlled study is the first RCT to evaluate the effects of G-CSF on the prevention of FN in patients with ovarian cancer. Treatment with G-CSF per physician discretion showed inferior outcomes for FN and myelosuppression. However, prophylactic treatment with short-acting G-CSF according to a stringent protocol would probably not result in such inferior outcomes. In a systematic review and meta-analysis, the weight of evidence from RCTs indicates little difference in efficacy between the short-acting and long-acting G-CSFs if dosed according to recommended guidelines. It was suggested long-acting G-CSFs in non-RCTs had greater efficacy, which may be a result of the underdosing of short-acting G-CSF in general practice in real-world usage.10 However, based on the findings of a systematic review of real-world comparative effectiveness studies, the risks of FN and FN-related complications are generally lower for prophylaxis with pegfilgrastim versus prophylaxis with short-acting ...
Results. Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AH, , , Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup., J. Natl. Cancer Inst., 2007, 99, 2, 112-128, doi: 10.1093/jnci/djk015.. ...
By James C. Shehan -. FDAs Oncologic Drugs Advisory Committee unanimously voted in favor of approval of EP2006, Novartiss biosimilar version of Amgens Neupogen® (filgrastim) for all five of the indications for which Neupogen is approved. This ground-breaking event manages to both move the US a little closer to the long-awaited first approval of a BPCIA biosimilar and to highlight the challenges biosimilars have overcome and the open issues they still face before winning FDA approval, launching and gaining market acceptance. Among those issues are what the generic names will be, the standard for interchangeability and the applicability of the patent dance provisions.. Novartis announced in July that EP2006 was the first 351(k) application accepted for review by FDA, an event that occurred almost 4 12 years after passage of the BPCIA. Neupogen was first approved in February 1991 and is a relatively simple biologic, checking in at 175 amino acids. Amgen sold about $1.2B of Neupogen last year. ...
Definition of Colony-stimulating factors in the Legal Dictionary - by Free online English dictionary and encyclopedia. What is Colony-stimulating factors? Meaning of Colony-stimulating factors as a legal term. What does Colony-stimulating factors mean in law?
Our results demonstrate that STZ-treated diabetic mice show a similar impairment in the G-CSF-induced mobilization of HSPCs to that observed in humans and that this defect is not the consequence of reduced bone marrow HSPC content or an intrinsic HSPC defect. Rather, the data support a model in which cells of the microenvironment are perturbed in diabetes and lose their ability to modulate CXCL12 expression in response to specific stimuli. Altered CXCL12 expression may blunt HSPC release from the bone marrow and can be overcome by direct pharmacological inhibition of the interaction of CXCL12 with its CXCR4 receptor.. The preservation or increase in HSPC numbers we observed is in contrast to recent reports of reduced LSK cells in diabetic mice (37, 38). These differences may reflect species differences or the long-term consequences of diabetes disease, which we did not assess in this study. All mice used in our experiments were ,12 weeks of age. For the STZ model, animals were analyzed 5 to 8 ...
PURPOSE: To support multicyclic, dose-intensive chemotherapy, we assessed the effects of reinfusing hematopoietic progenitors collected at each cycle in leukapheresis product or whole blood. PATIENTS AND METHODS: Twenty-five patients with small-cell lung cancer (SCLC) were treated with six cycles of ifosfamide, carboplatin, and etoposide (ICE) with granulocyte colony-stimulating factor (G-CSF) 300 micrograms/d subcutaneously (SC) on days 4 to 15. Hematopoietic progenitors collected during each cycle were reinfused on day 3 of the next cycle. Cohort 1 (n = 6) was treated every 3 weeks, with leukapheresis after 2 weeks and cryopreservation of the leukapheresis product. Chemotherapy was given if the WBC count was , or = 3 x 10(9)/L and platelet count , or = 100 x 10(9)/L. Cohort 2 (n = 7) was treated every 2 weeks, with leukapheresis on day 1 of the next cycle and storage of the leukapheresis product at 4 degrees C. Cohort 3 (n = 12) was treated every 2 weeks, with 500 to 750 mL of blood drawn by ...
Unclear. It is postulated that the pathogenesis of Sweet Syndrome is driven by helper T cells through the production of several cytokines, such as interleukin-1, interleukin-2, and interferon-gamma, as well as granulocyte colony-stimulating factor (G-CSF). It appears to be in some cases a response to systemic factors (hematological disease, infection, or drug exposure to granulocyte colony-stimulating factor, minocycline, Bactrim, lithium, furosemide, hydralazine, carbamazepine, and levonorgestrel/ethinyl estradiol). There is a neutrophil mediation, associated neutrophilia, and response to medications that impact neutrophil activity. Drugs implicated include G-CSF, all-trans-retinoic acid, trimethoprim-sulfamethoxazole, and azathioprine. ...
The vast majority of hematopoietic stem cells (HSCs) reside in specialized niches within the bone marrow during steady state, maintaining lifelong blood cell production. A small number of HSCs normally traffic throughout the body; however, exogenous stimuli can enhance their release from the niche and entry into the peripheral circulation. This process, termed mobilization, has become the primary means to acquire a stem cell graft for hematopoietic transplant at most transplant centers. Currently, the preferred method of HSC mobilization for subsequent transplantation is treatment of the donor with granulocyte colony-stimulating factor. The mobilizing effect of granulocyte colony-stimulating factor is not completely understood, but recent studies suggest that its capacity to mobilize HSCs, at least in part, is a consequence of alterations to the hematopoietic niche. The present article reviews some of the key mechanisms mediating HSC mobilization, highlighting recent advances and controversies ...
Looking for colony-stimulating factor? Find out information about colony-stimulating factor. A group of lymphocytes that induce the maturation and proliferation of leukocyte, macrophage, and monocyte lines present in bone marrow Explanation of colony-stimulating factor
A recent abstract presented at the American Society of Clinical Oncology (ASCO) annual meeting compared 2 risk models for patients with intermediate chemotherapy-induced neutropenia (CIN) risk and compared them to guidelines from ASCO and the National Comprehensive Cancer Network to determine when colony-stimulating factor should be ideally used to prevent CIN.|br /| ​​​​​​
Copyright 2013 by the Massachusetts General Hospital. Some sections copyright 2008-2009 by The President and Fellows of Harvard College.. ...
Dendritic cells (DCs)3 constitute a system of rare APCs that play crucial roles in the elicitation of T cell-dependent immunity (1, 2). The development of DCs is considered to occur in distinct stages. Proliferating DC progenitors in the bone marrow develop into DC precursors, which circulate in the blood. These give rise to immature DCs, which are strategically positioned in various nonlymphoid tissues in the body where they can capture and process Ags from invading pathogens. Proinflammatory signals that are often triggered by infectious agents initiate the maturation of these DCs and their migration to the T cell-rich areas of the lymph nodes and spleen, where they present captured Ags to naive T cells (1, 2). Ag-specific clonal expansion is initiated, and this eventually leads to elimination of the pathogen and establishment of immunological memory.. Although it is known that DCs are critical in initiating T cell immunity, emerging evidence suggests that DCs also play roles in the regulation ...
Objectives: Granulocyte-colony stimulating factor (G-CSF) is known to induce the myeloid-derived suppressor cell (MDSC) to stimulate the progression of uterine cervical cancer. The aim of the current study is to investigate the role of MDSC in the induction of cancer stem cells in uterine cervical cancer.. Methods: We first established cervical cancer cell lines stably transfected with G-CSF expression vector (ME180-GCSF) or control vector (ME180-control). Then, using BALB/c nude mice subcutaneously inoculated with ME180-G-CSF or ME180-control cells, the effect of G-CSF on the induction of MDSCs (CD11b+Gr1+ cells) and cancer stem cells (ALDH-high cells) were assessed by flow cytometry. Using MDSCs isolated from the spleens of ME180-GCSF-bearing mice, we next investigated whether the MDSCs induce cancer stem cells in vitro. Finally, we analyzed the association between the G-CSF expression and ALDH1A1 expression in human cervical cancer specimens by immunohistochemistry.. Results: 1) G-CSF induces ...
Bone marrow is collected via multiple aspirations from the posterior-superior iliac crest in a sterile environment (usually a surgical operating room) while the patient is under anesthesia. Ideally, HPCs should be collected while the patients marrow is normocellular and uninvolved by the malignancy. Currently, bone marrow HPC collection is rarely, if ever, done for the purpose of autologous transplantation because HPCs can be collected from peripheral blood and engraft more rapidly when collected this way. Hematopoietic progenitor cells are normally infrequent in the blood but are mobilized into the blood during the recovery after chemotherapy and following treatment with granulocyte colony-stimulating factor (G-CSF). Peripheral blood progenitor cells (PBPCs) are collected using apheresis with continuous-flow cell separation. One to four daily apheresis sessions are usually required to achieve the minimal target CD34+ cell dose (at least 2 × 106/kg). The collected PBPCs are subsequently ...
...Putnam Valley NY. (June 19 2014) Researchers in Taiwan have found t...The study will be published in a future issue of Cell Transplantat... Currently OA treatment involves the use of anti-inflammatory drugs ...While the beneficial effects of G-CSF-mobilized peripheral blood stem ...,Stem,cell,mobilization,therapy,may,effectively,treat,osteoarthritis,biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters
The second derivative amplitudes at 270.4 and 230.2 nm were selected for the assay of trifluoperazine hydrochloride and isopropamide iodide, respectively. This might be due to the fact that many of these patients undergo surgical commissurotomy due to the technical difficulties involved in a percutaneous procedure in general. Three different kinds of polymers are presented: polystyrene which serves as reference polymer, polyphosphazenes which behave abnormally in solution and poly(ethylene oxide) which is soluble in water. The Asthma Control Test (ACT) is a five-item questionnaire for the assessment of asthma control.. Clinical effect of granulocyte colony-stimulating factor on neutrophils and leukemic cells in myelogenous leukemia: analysis. All participants were genotyped for the length of the CAG (cytosine-adenine-guanine) repeat in exon 1 of the androgen receptor gene using PCR and subsequent fragment analysis on sequence analyzer. Statistically significant covariation between the ontogeny ...
Granulocyte colony-stimulating factor (GCSF) is the principal growth factor regulating the maturation, proliferation and differentiation of the precursor cells of neutrophilic granulocytes and is used to treat neutropenia. GCSF is a member of the long-chain subtype of the class 1 cytokine superfamily, which includes growth hormone, erythropoietin, interleukin 6 and oncostatin M. Here we have determined the crystal structure of GCSF complexed to the BN-BC domains, the principal ligand-binding region of the GCSF receptor (GCSFR). The two receptor domains form a complex in a 2:2 ratio with the ligand, with a non-crystallographic pseudo-twofold axis through primarily the interdomain region and secondarily the BC domain. This structural view of a gp130-type receptor-ligand complex presents a new molecular basis for cytokine-receptor recognition. Atomic structure of the GCSF-receptor complex showing a new cytokine-receptor recognition scheme.,Aritomi M, Kunishima N, Okamoto T, Kuroki R, Ota Y, ...
The host defense response critically depends on the production of leukocytes by the marrow and the controlled delivery of these cells to relevant sites of inflammation/infection. The cytokine granulocyte-colony stimulating factor (G-CSF) is commonly used therapeutically to augment neutrophil recovery following chemo/radiation therapy for malignancy, thereby decreasing infection risk. Although best known as a potent inducer of myelopoiesis, we previously reported that G-CSF also promotes the delivery of leukocytes to sites of inflammation by stimulating expression of potent E-selectin ligands, including an uncharacterized ∼65-kDa glycoprotein. To identify this ligand, we performed integrated biochemical analysis and mass spectrometry studies of G-CSF-treated primary human myeloid cells. Our studies show that this novel E-selectin ligand is a glycoform of the heavy chain component of the enzyme myeloperoxidase (MPO), a well-known lysosomal peroxidase. This specialized MPO glycovariant, referred ...
To investigate the functional properties of IL-2 and TNF alpha on leukemic B cells, we evaluated (1) the regulation of expression of TNF receptors (TNF-R) and IL-2 receptors on leukemic B cells after culture with TNF alpha and IL-2; (2) the effect of the combination of TNF alpha and IL-2 in a proliferative in vitro assay; and (3) the expression and regulation by these cytokines of receptors for hematopoietic factors, including IL-3, granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF ...
(1) To perform a comprehensive analysis of the time elapsed between the last G-CSF injection and the PET/CT examination on the biodistribution of 18F-FDG, with emphasis on liver, spleen, and bone marrow uptake, and (2) to investigate whether an inversion of the liver to spleen ratio affects the Deauville scoring. Retrospectively included were 74 consecutive diffuse large B cell lymphoma (DLBCL) patients referred for baseline and interim examinations and receiving immunochemotherapy with various G-CSF regimens. A comprehensive evaluation considering baseline metabolic active tumour volume (MATV), factors affecting liver uptake, the type of G-CSF, and the time elapsed between chemotherapy/G-CSF and interim PET/CTs was performed. Mean (± SD) percentage variations between baseline and interim PET/CTs (i-PET/CT) for bone marrow (%Variation_BONE), liver (%Variation_LIVER) and spleen (%Variation_SPLEEN) were equal to 32.0 ± 46.9%, 16.1 ± 42.8%, and 10.6 ± 51.1 %, respectively. %Variation_LIVER and
Somlo G, Sniecinski I, ter Veer A, Longmate J, Knutson G, Vuk-Pavlovic S, Bhatia R, Chow W, Leong L, Morgan R, Margolin K, Raschko J, Shibata S, Tetef M, Yen Y, Forman S, Jones D, Ashby M, Fyfe G, Hellmann S, Doroshow JH. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. Blood. 1999 May 1; 93(9):2798-806 ...
We retrospectively compared the incidence of neutropenia in two groups of HIV patients with lymphoma, who underwent chemotherapy supported by once-per-cycle administration of pegfilgrastim or by daily subcutaneous injection of filgrastim, respectively. Our findings indicate that pegfilgrastim and filgastrim produce similar results in preventing both neutropenia and febrile neutropenia.
Pegfilgrastim was evaluated in three randomized, double-blind, controlled studies. Studies 1 and 2 were active-controlled studies that employed doxorubicin 60 mg/m2 and docetaxel 75 mg/m2 administered every 21 days for up to 4 cycles for the treatment of metastatic breast cancer. Study 1 investigated the utility of a fixed dose of pegfilgrastim. Study 2 employed a weight-adjusted dose. In the absence of growth factor support, similar chemotherapy regimens have been reported to result in a 100% incidence of severe neutropenia (ANC , 0.5 x 109/L) with a mean duration of 5 to 7 days and a 30% to 40% incidence of febrile neutropenia. Based on the correlation between the duration of severe neutropenia and the incidence of febrile neutropenia found in studies with filgrastim, duration of severe neutropenia was chosen as the primary endpoint in both studies, and the efficacy of pegfilgrastim was demonstrated by establishing comparability to filgrastim-treated patients in the mean days of severe ...
This type is refractory to granulocyte colony-stimulating factor. There is an absence of lysosomes in fibroblasts and depletion ... Most cases of SCN respond to treatment with granulocyte colony-stimulating factor (filgrastim), which increases the neutrophil ... Over 90% of SCN responds to treatment with granulocyte colony-stimulating factor (filgrastim), which has significantly improved ... Neutrophil survival is normal.[citation needed] Regular administration of exogenous granulocyte colony-stimulating factor ( ...
Granulocyte colony-stimulating factor (G-CSF), available as filgrastim, can reduce the risk of infection. In some cases, G-CSF ... "Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European Study on Glycogen Storage ... "Different effects of granulocyte colony-stimulating factor and erythropoietin on erythropoiesis". Stem Cell Research & Therapy ... "Thrombocytopenia in association with splenomegaly during granulocyte-colony-stimulating factor treatment in mice is not caused ...
... (tradename Leukine) is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that functions as ... "Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor". Blood. 92 (12): 4491-508. doi: ... it can also activate mature granulocytes and macrophages, and can contribute to the differentiation of megakaryocytic ...
One notable example is the granulocyte macrophage colony-stimulating factor. There are two main categories of immunostimulants ... For example, female sex hormones are known to stimulate both adaptive and innate immune responses. Some autoimmune diseases ... Dorshkind, Kenneth; Horseman, Nelson D. (1 June 2000). "The Roles of Prolactin, Growth Hormone, Insulin-Like Growth Factor-I, ... Immunostimulants, also known as immunostimulators, are substances (drugs and nutrients) that stimulate the immune system by ...
Research regarding the production of granulocyte colony stimulating factor (G-CSF) is being conducted to investigate AMML ... "Production of granulocyte colony-stimulating factor by acute myelomonocytic leukemia cells". Leukemia Research. 12 (9): 745-750 ... Acquired predisposing factors include:Aplastic anemia, Chemotherapy, prenatal exposure to tobacco, marihuana, and alcohol. ... "Acute Myeloid Leukemia (AML) Subtypes and Prognostic Factors". www.cancer.org. Retrieved 2019-12-14. Shirafuji, Naoki; Asano, ...
Production is stimulated by granulocyte macrophage colony-stimulating factor (GM-CSF). There is some controversy over which ... CFU-GM, also known as granulocyte-macrophage progenitor (GMP), is a colony forming unit. It is derived from CFU-GEMM. The "GM" ... Nomenclature of hematopoietic colonies and lineages "Hem I WBC Morphology and Physiology". Archived from the original on ... stands for "granulocyte, monocyte". It is the precursor for monoblasts and myeloblasts. ...
There is limited evidence that granulocyte colony-stimulating factor may not hasten the resolution of diabetic foot ulcer ... Cochrane Wounds Group) (August 2013). "Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot ... Growth factors - there is some low-quality evidence that growth factors may increase the likelihood that diabetic foot ulcers ... Binding of growth factors is clearly an important role of perlecan in wound healing and angiogenesis. Poor wound healing in ...
El Ouakfaoui S, Heitz D, Paquin R, Beaulieu AD (February 1999). "Granulocyte-macrophage colony-stimulating factor modulates ...
IL-3 shares the β subunit with IL-5 and granulocyte-macrophage colony-stimulating factor (GM-CSF). This β subunit sharing ... Sometimes also called colony-stimulating factor, multi-CSF, mast cell growth factor, MULTI-CSF, MCGF; MGC79398, MGC79399: the ... Granulocyte macrophage colony-stimulating factor (GM-CSF), and IL-6. IL-3 is secreted by basophils and activated T cells to ... "Granulocyte-Macrophage colony stimulating factor and interleukin 3: Target cells and kinetics of response in vivo". Stem Cells ...
Granulocyte-colony stimulating factor (G-CSF) is one possible treatment for neutropenia. Monitoring weight gain and growth is ...
"Human osteoblasts support hematopoiesis through the production of granulocyte colony-stimulating factor". J. Exp. Medicine. 179 ... and Osteopontin that can stimulate Wnt signaling in HSCs. Transcription factors such as PITX2 must be expressed in stromal ... or the granulocyte/macrophage progenitor (GMP), which gives rise to the granulocytes of the innate immune response. MEP ... These chimeric transcription factors can result in the improper repression or activation of the target gene, as well as the ...
These include granulocyte colony-stimulating factor (GCSF) and myelomonocytic growth factor (MGF). GCSF acts in hematopoiesis ... Secondary structure analysis has suggested similarity to IL4 and granulocyte-macrophage colony stimulating factor (GMCSF). ... "Disulfide structures of human interleukin-6 are similar to those of human granulocyte colony stimulating factor". Archives of ... "Characterization of a human multilineage-colony-stimulating factor cDNA clone identified by a conserved noncoding sequence in ...
Nagata identified Interferon in 1980 and Granulocyte colony-stimulating factor in 1986. He also identified a death factor (Fas ... "Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor". Nature. 319 (6052): 415-8. Bibcode: ... a novel member of the tumor necrosis factor family". Cell. 75 (6): 1169-78. doi:10.1016/0092-8674(93)90326-L. PMID 7505205. ...
Kaziro further broadened his research profile in 1986, when he began a genetic study on Granulocyte colony-stimulating factor ( ... "Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor". Nature. 319 (6052): 415-418. Bibcode ... Factor T is one of two complementary factors that are required for the elongation of peptide bonds on ribosomes within E. coli ... Factor T divides into Tu and Ts components, where in the presence of GTP, a Tu-Ts complex will dissociated to Tu and Ts, and ...
"CD34 expression by murine haematopoietic stem cells mobilized by granulocyte colony-stimulating factor". Blood. 96 (5): 1989-93 ... Kees UR, Ford J (Feb 1999). "Synergistic action of stem-cell factor and interleukin-7 in a human immature T-cell line". ... as a cell surface glycoprotein and functions as a cell-cell adhesion factor. It may also mediate the attachment of ... which are factor XIIIa-negative) in the interstitium and around the adnexa of dermis of skin, as well as cells in soft tissue ...
Ludwig researchers in Melbourne discovered and cloned the granulocyte-monocyte colony stimulating factor (GM-CSF) through a ... March 1985). "Structure and expression of the mRNA for murine granulocyte-macrophage colony stimulating factor". The EMBO ... The factor is essential to the maturation of key white blood cells, and has been used extensively over the past few decades to ... October 1985). "Purification and characterization of a human tumor necrosis factor from the LuKII cell line". Proceedings of ...
Administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) may increase recovery. Other known side ...
In EG cytokines IL-3, IL-5 and granulocyte macrophage colony stimulating factor (GM-CSF) may be behind the recruitment and ... granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis". Gastroenterology. 110 (3 ...
... is a recombinant granulocyte colony-stimulating factor which functions as an immunostimulator. It is developed by ...
Granulocyte macrophage colony-stimulating factor (GM-CSF) hypersensitivity of myeloid progenitors in vitro. These criteria are ... Immature granulocytes and nucleated red cells in the peripheral blood. White blood cell count >10 x 109/L. Clonal chromosomal ...
... colony-stimulating factor-1 receptor (CSF-1R) and granulocyte macrophage colony-stimulating factor (GM-CSF) in preclinical ... December 2010). "Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes ... A similar outcome was achieved by neutralizing macrophage colony-stimulating factor 1, which impaired the intratumoral ... insulin-like growth factors (IGF1 and IGF2), TGF-β, EGF, heparin-binding EGF-like growth factor (HB-EGF), and tumor necrosis ...
Granulocyte-Colony Stimulating Factor Alters the Pharmacodynamic Properties of Cocaine in Female Mice. ACS Chem Neurosci. 2019; ...
... is a recombinant granulocyte macrophage colony-stimulating factor which functions as an immunostimulator. Quittet ...
Granulocyte-macrophage colony stimulating factor expands the circulating hematopoietic progenitor cell compartment in humans, ... The effect of recombinant human granulocyte-macrophage colony stimulating factor on chemotherapy-induced myelosuppression. N ... Antman developed standards for the treatment of patients receiving chemotherapy including pharmacology, growth factors and ...
Granulocyte-macrophage colony-stimulating factor (GM-CSF) upregulates CCL17 production in monocytes and macrophages. Dendritic ... It does not interact with granulocytes. It acts as a powerful chemoattractant to T-helper cells and T-regulatory cells because ... Cytokines, like CCL17, help cells communicate with one another, and stimulate cell movement. Chemokines are a type of cytokine ... CCL17 is expressed constitutively in the thymus, but only transiently in phytohemagglutinin-stimulated peripheral blood ...
... in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy". Blood. 82 (3): 931-9 ...
Plasmapheresis and administration of granulocyte colony-stimulating factor were used to treat the blood abnormalities. The ...
Carr R, Brocklehurst P, Doré CJ, Modi N (January 2009). "Granulocyte-macrophage colony stimulating factor administered as ... Granulocyte-macrophage colony stimulating factor (GM-CSF) is sometimes used in neonatal sepsis. However, a 2009 study found ... Infants showing no signs of neonatal sepsis will have a sepsis workup done only if concerning factors are shown. Only a small ... The child can contribute to the onset of sepsis through multiple factors. Mothers contribute to the risk through a variety of ...
"Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis". ... granulocyte colony-stimulating factor) for neutropenia Nplate (romiplostim) for chronic immune thrombocytopenic purpura ... a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products ... the first rheumatoid arthritis drug targeting tumor necrosis factor alpha (TNF-alpha). A 2006 assessment by the National ...
Neutropenia may be treated with granulocyte-colony stimulating factor (GCSF) to boost peripheral neutrophil counts. However, ... It has also been shown that the Dictyostelium discoideum homologue catalyzes the removal of eukaryotic initiation factor 6 ( ... by effecting release and recycling of the nucleolar shuttling factor Tif6. This is required for 60S maturation and ...
The peripheral stem cell yield is boosted with daily subcutaneous injections of Granulocyte-colony stimulating factor, serving ... and the colony-stimulating factor used (G-CSF). G-CSF drugs include filgrastim (Neupogen, Neulasta), and lenograstim (Graslopin ...
株落刺激(英語:Template:Colony-stimulating factors). *血基質和卟啉 *代謝酶 ... 單核球和顆粒球(英語:Template:Monocyte and
株落刺激(英語:Template:Colony-stimulating factors). *血紅素和卟啉 *代謝酶 ... 單核白血球和顆粒白血球(英語:Template:Monocyte and granulocyte disease) ... MeSH(醫學主題詞
... granulocyte - granulocyte macrophage-colony stimulating factor (GM-CSF) - granulocyte-colony stimulating factor (G-CSF) - ... host factors - HPTN - HPV - HRSA - HTLV-I - HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) - HTLV-II - ...
... granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated ...
Granulocyte macrophage colony-stimulating factor. *Milodistim. *Molgramostim. *Regramostim. *Sargramostim. *Antibodies: ... tumor necrosis factor-activated receptor activity. • nerve growth factor binding. Cellular component. • cytoplasm. • integral ... "Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation". The ... "Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation". The ...
... as persistent joint pain has been associated with elevated levels of IL-6 and granulocyte-macrophage colony-stimulating factor ... January 2010). "Factors associated with persistence of arthralgia among Chikungunya virus-infected travellers: report of 42 ... mouse studies suggest that IPS-1 is an important factor,[48] and that IRF3 and IRF7 are important in an age-dependent manner.[ ... "Interferon response factors 3 and 7 protect against Chikungunya virus hemorrhagic fever and shock". Journal of Virology. 86 ...
Granulocyte-macrophage colony-stimulating factor. *Interferon-gamma. References[edit]. *^ Julius M. Cruse; Robert Edwin Lewis ( ...
... granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-15 belongs to ... "Cytokine & Growth Factor Reviews. 22 (2): 99-108. doi:10.1016/j.cytogfr.2011.04.001. PMC 3994286. PMID 21531164.. ... IL-15 was discovered in 1994 by two different laboratories, and characterized as T cell growth factor.[5] Together with ... Growth Factor Reviews. 22 (1): 19-33. doi:10.1016/j.cytogfr.2010.09.003. PMID 21074481.. ...
株落刺激(英语:Template:Colony-stimulating factors). *血基質和卟啉 *代謝酶 ... 單核球和顆粒球(英语:Template:Monocyte and
... and granulocyte-macrophage colony stimulating factor (GM-CSF).[28] AU-rich elements also regulate the biosynthesis of proto- ... Messages that are being actively translated are bound by ribosomes, the eukaryotic initiation factors eIF-4E and eIF-4G, and ... In some instances, small RNA molecules (sRNA) tens to hundreds of nucleotides long can stimulate the degradation of specific ... "Multiple processing body factors and the ARE binding protein TTP activate mRNA decapping" (PDF), Mol. Cell, 20 (6): 905-15, ...
... induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor". ... Hepatocyte growth factor (HGF) or scatter factor (SF) is a paracrine cellular growth, motility and morphogenic factor. It is ... "Entrez Gene: HGF hepatocyte growth factor (hepapoietin A; scatter factor)".. *^ Yang ZJ, Zhang YR, Chen B, Zhang SL, Jia EZ, ... Nakamura T (1992). "Structure and function of hepatocyte growth factor". Progress in Growth Factor Research. 3 (1): 67-85. doi: ...
... of leukocytes and in human neutrophils treated with granulocyte macrophage colony-stimulating factor and then stimulated with ... For example, chemotactic factors stimulate human neutrophils to raise cytosolic Ca2+ which triggers cPLA2s, particularly the α ... platelet-activating factor, to stimulate and otherwise activate eosinophils.[18][38][39][40] ... potent chemotactic factor, LTB4, and possibly also weaker chemotactic factor, 5S-HETE, which serve to attract and otherwise ...
... epidermal growth factor,[30] granulocyte-macrophage-stimulating growth factor,[31] platelet-derived growth factor,[31] vascular ... Flidel-Rimon O, Roth P (November 1997). "Effects of milk-borne colony stimulating factor-1 on circulating growth factor levels ... endothelial growth factor,[32] and colony-stimulating factor-1.[33]. Notably in humans a lack of colostrum production is linked ... Colostrum also contains a number of growth factors, such as insulin-like growth factors I (IGF-1),[24] and II,[25] transforming ...
... granulocyte-colony-stimulating factor, e.g., filgrastim, lenograstim).. In very severe myelosuppression, which occurs in some ... It is caused by the interaction between genetic susceptibility and environmental factors.[124][125] These factors lead to ... Neutropenia (a decrease of the neutrophil granulocyte count below 0.5 x 109/litre) can be improved with synthetic G-CSF ( ... The susceptibility of an individual to liver damage can be altered by other factors such as the cancer itself, viral hepatitis ...
colony-stimulating. *heme and porphyrin *metabolism. *intermediates. Disease. *Red blood cell. *Megakaryocyte ... Monocyte and granulocyte. *Neoplasms and cancer. *Histiocytosis. *Symptoms and signs. *Blood tests *findings ...
... ଗ୍ରାନୁଲୋସାଇଟ କଲୋନି-ସ୍ଟିମୁଲେଟିଙ୍ଗ ଫ୍ୟାକ୍ଟରgranulocyte colony-stimulating factor (G-CSF) ସ‌ହିତ ଫିଲଗ୍ରାସ୍ଟିମର ସାମଞ୍ଜସ୍ୟ ଅଛି ।[୧] ...
... a process known as apheresis after a certain period of daily subcutaneous injections of Granulocyte-colony stimulating factor, ... technology to treat malignant hematological diseases and tumors by infusing patients with granulocyte colony-stimulating factor ...
株落刺激(英語:Template:Colony-stimulating factors). *血基質和卟啉 *代謝(英語:Template:Porphyrin metabolism enzymes) ... 單核球和顆粒球(英語:Template:Monocyte and granulocyte disease) ... 抑制 II、VII(英語:Factor VII)、IX(英語:Factor IX)、X(英語:Factor X)) ... 凝血因子X(英語:Factor X)缺乏
title =A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population ...
Granulocyte macrophage colony-stimulating factor. *Milodistim. *Molgramostim. *Regramostim. *Sargramostim. *Antibodies: ... Hertzog PJ, Williams BR (June 2013). "Fine tuning type I interferon responses". Cytokine & Growth Factor Reviews. 24 (3): 217- ... binding interferon-stimulated response elements (ISRE) and gamma activating sequences (GAS), promoting gene transcription.[7][ ... type I IFNs induce interferon-stimulated gene (ISG) expression, classically resulting in a robust anti-viral immune response. ...
Granulocyte macrophage colony-stimulating factor. *Milodistim. *Molgramostim. *Regramostim. *Sargramostim. *Antibodies: ... tumor necrosis factor receptor superfamily binding. • tumor necrosis factor receptor binding. • receptor binding. • zinc ion ... TRAIL has also been designated CD253 (cluster of differentiation 253) and TNFSF10 (tumor necrosis factor (ligand) superfamily, ... The TRAIL gene lacks TATA and CAAT boxes and the promoter region contains putative response elements for transcription factors ...
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from ... Dendritic cells can be stimulated to activate a cytotoxic response towards an antigen. Dendritic cells, a type of antigen ... Cancer immunotherapy attempts to stimulate the immune system to destroy tumors. A variety of strategies are in use or are ... The cells are expanded non-specifically and/or stimulated. The cells are then reinfused and produce an immune response against ...
Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections PMID 23955465 https://doi.org/10.1002 ... Done Individual recovery expectations and prognosis of outcomes in non-specific low back pain: prognostic factor review PMID ... Done Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious ... Done Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema PMID 29669176 ...
These same compounds also increase secretion of macrophage colony-stimulating factor by osteoblasts, which promotes the ... and 50-100 billion granulocytes are produced in this way.[13] ... These factors include insulin-like growth factors I and II, ... Growth factor storage - mineralized bone matrix stores important growth factors such as insulin-like growth factors, ... transforming growth factor-beta, fibroblast growth factor, platelet-derived growth factor, and bone morphogenetic proteins.[45] ...
Not to be confused with granulocyte macrophage colony-stimulating factor.. Granulocyte-colony stimulating factor (G-CSF or GCSF ... "Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) secretion by ... growth factor activity. • granulocyte colony-stimulating factor receptor binding. Cellular component. • extracellular region. • ... Duarte RF, Franf DA (June 2002). "The synergy between stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF ...
株落刺激(英语:Template:Colony-stimulating factors). *血基質和卟啉 *代謝酶 ... 單核球和顆粒球(英语:Template:Monocyte and granulocyte disease) ... 抑制 II、VII(英语:Factor VII)、IX(英语:Factor IX)、X(英语:Factor X)) ... 肝素經由它的硫化五糖序列與酵素
Granulocyte macrophage colony-stimulating factor. *Milodistim. *Molgramostim. *Regramostim. *Sargramostim. *Antibodies: ... "Information on Erythropoiesis Stimulating Agents (ESA) (marketed as Procrit, Epogen, and Aranesp)". U.S. Food and Drug ... "Erythropoiesis Stimulating Agents: Aranesp (darbepoetin alfa), Epogen (epoetin alfa), and Procrit (epoetin alfa)". MedWatch - ... In March 2008, a panel of advisers for the U.S. Food and Drug Administration (FDA) supported keeping erythropoiesis-stimulating ...
1995). "Association of granulocyte-macrophage colony-stimulating factor with the crystalloid granules of human eosinophils". ... 1992). "Purification and cDNA cloning of a novel factor produced by a human T-cell hybridoma: sequence homology with animal ...
Vaccination with irradiated granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting gene-transduced cancer vaccines ... with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, ... granulocyte- macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 ... granulocyte-macrophage colony-stimulating factor; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; RCR ...
"Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) secretion by ... Granulocyte colony-stimulating factor (G-CSF or GCSF), also known as colony-stimulating factor 3 (CSF 3), is a glycoprotein ... Duarte RF, Franf DA (June 2002). "The synergy between stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF ... "The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors". Proceedings of the ...
The granulocyte colony-stimulating factor receptor (G-CSF-R) also known as CD114 (Cluster of Differentiation 114) is a protein ... The granulocyte colony-stimulating factor receptor is present on precursor cells in the bone marrow, and, in response to ... "Entrez Gene: CSF3R colony stimulating factor 3 receptor (granulocyte)". Mehta, H M; Futami, M; Glaubach, T; Lee, D W; Andolina ... G-CSF-R is a cell-surface receptor for the granulocyte colony-stimulating factor (G-CSF). The G-CSF receptors belongs to a ...
Not to be confused with granulocyte macrophage colony-stimulating factor.. Granulocyte-colony stimulating factor (G-CSF or GCSF ... "Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) secretion by ... growth factor activity. • granulocyte colony-stimulating factor receptor binding. Cellular component. • extracellular region. • ... Duarte RF, Franf DA (June 2002). "The synergy between stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF ...
The hematopoietic growth factor, granulocyte macrophage colony-stimulating factor (GM-CSF), is considered to play a central ... Granulocyte Macrophage Colony-Stimulating Factor. Jonathan L. McQualter, Rima Darwiche, Christine Ewing, Manabu Onuki, Thomas W ... Granulocyte Macrophage Colony-Stimulating Factor. Jonathan L. McQualter, Rima Darwiche, Christine Ewing, Manabu Onuki, Thomas W ... 1997) Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice. Ann. Rheum. Dis. 56:364- ...
... especially granulocytes, macrophages, and cells that become platelets, to multiply and mature. A laboratory-produced version of ... Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Granulocyte Macrophage-Colony Stimulating Factor Speaker ... A protein that stimulates white blood cells, especially granulocytes, macrophages, and cells that become platelets, to multiply ... A protein that stimulates white blood cells, ...
Surfactant metabolism in transgenic mice after granulocyte macrophage-colony stimulating factor ablation.. Ikegami M1, Ueda T, ... Mice made granulocyte macrophage-colony stimulating factor (GM-CSF)-deficient by homologous recombination maintain normal ... Granulocyte-Macrophage Colony-Stimulating Factor/physiology*. *Lysophosphatidylcholines/administration & dosage. * ...
... increases the number of circulating granulocytes and decreases TNF production while improving survival in sepsis models. To ... Granulocyte colony-stimulating factor (G-CSF) increases the number of circulating granulocytes and decreases TNF production ... The use of granulocyte colony-stimulating factor after liver transplantation Transplantation. 1995 Jun 15;59(11):1557-63. ... Univariate and logistic regression analysis of risk factors for sepsis and rejection revealed no difference between the two ...
Granulocyte colony-stimulating factor treatment for cyclophosphamide-induced severe neutropenia in Wegeners granulomatosis.. ... To examine the efficacy and safety of recombinant human granulocyte colony-stimulating factor (rHuG-CSF) in the treatment of ... Granulocyte Colony-Stimulating Factor/therapeutic use*. *Granulomatosis with Polyangiitis/blood*. *Granulomatosis with ...
Root RK, Dale DC: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and ... Granulocyte colony-stimulating factor (G-CSF) is an endogenous hematopoietic growth factor that induces terminal ... Are Granulocyte Colony-Stimulating Factors Beneficial in Treating Diabetic Foot Infections?. Mario Cruciani, Benjamin A. Lipsky ... Are Granulocyte Colony-Stimulating Factors Beneficial in Treating Diabetic Foot Infections?. Mario Cruciani, Benjamin A. Lipsky ...
Granulocyte colony-stimulating factor (G-CSF) is a naturally occurring glycoprotein that is synthesized by stromal cells in ... Lieschke GJ, Burgess AW (1992) Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N ... Tani K, Ozawa K, Ogura H et al (1990) Expression of granulocyte and granulocyte-macrophage colony-stimulating factors by human ... Granulocyte colony-stimulating factor (G-CSF) is a naturally occurring glycoprotein that is synthesized by stromal cells in ...
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is often used to treat leucopenia. Other haematopoietins may increase ... Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta- ... Haematopoietic growth factor Granulocyte-macrophage colony-stimulating factor Innate immunity Adaptive immunity ... Macrophage tumor necrosis factor-alpha induces epithelial expression of granulocyte-macrophage colony-stimulating factor: ...
Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils. By JC Gasson, RH Weisbart, SE ... Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils. By JC Gasson, RH Weisbart, SE ... Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils Message Subject. (Your Name) has ... The NIF-T was found to potently stimulate the growth of granulocyte and macrophage colonies from human bone marrow and colony ...
... the granulocytes and the monocytes-macrophages. This CSF induces granulocytes. ... Granulocyte/macrophage colony-stimulating factors are cytokines that act in hematopoiesis by controlling the production, ... Granulocyte colony-stimulating factorAdd BLAST. 178. Amino acid modifications. Feature key. Position(s). DescriptionActions. ... granulocyte colony-stimulating factor receptor binding Source: MGI ,p>Inferred from Physical Interaction,/p> ,p>Covers physical ...
GM-CSF stands for Granulocyte-Macrophage-Macrophage Colony-Stimulating Factor (pharmacology). GM-CSF is defined as Granulocyte- ... Macrophage-Macrophage Colony-Stimulating Factor (pharmacology) very rarely. ... How is Granulocyte-Macrophage-Macrophage Colony-Stimulating Factor (pharmacology) abbreviated? ... a href=https://www.acronymfinder.com/Granulocyte_Macrophage_Macrophage-Colony_Stimulating-Factor-(pharmacology)-(GM_CSF).html ...
Granulocyte macrophage colony-stimulating factor. Granulocyte colony-stimulating factor. Macrophage colony-stimulating factor. ... "Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) secretion by ... Granulocyte Colony-Stimulating Factor (G-CSF or GCSF) is a colony-stimulating factor hormone. It is a glycoprotein, growth ... Duarte RF, Franf DA (2003). "The synergy between stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF): ...
Have not received prophylactic granulocyte colony-stimulating factors but who have one or more risk factors for an infection- ... Have not received prophylactic granulocyte colony-stimulating factors but who have one or more risk factors for an infection- ... The class of drugs known as granulocyte colony stimulating factors (G-CSFs) include: Filgrastim (Neupogen®), Filgrastim-sndz, ( ... The class of drugs known as granulocyte colony stimulating factors (G-CSFs) include: Filgrastim (Neupogen®), Filgrastim-sndz, ( ...
A naturally occurring protein that stimulates the production of granulocytes and macrophages by stem cells and is used as a ... n. A naturally occurring protein that stimulates the production of granulocytes and macrophages by stem cells and is used as a ...
... to tumor escape from host immune surveillance and to cancer progression by production of tumor-promoting soluble factors.... ... Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells ... Granulocyte colony-stimulating factor (G-CSF) is a principle cytokine controlling granulocyte number. Recombinant human G-CSF ( ... Huang X, Liu Y, Bai S, Peng L, Zhang B, Lu H (2017) Granulocyte colony stimulating factor therapy for stroke: a pairwise meta- ...
Granulocyte-macrophage colony-stimulating factor (GM-CSF) can stimulate proliferation of leukemic blasts and sensitize these ... Granulocyte-macrophage colony-stimulating factor (GM-CSF) can stimulate proliferation of leukemic blasts and sensitize these ... Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly ... Rossi, H., ODonnell, J., Sarcinelli, F. et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with ...
Because granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) enhance ... granulocyte and macrophage number and function, their use in the management of … ... Because granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) enhance ... Granulocyte and granulocyte-macrophage colony-stimulating factors in cord and maternal serum at delivery Pediatr Res. 1994 Feb; ...
Synonyms: CSF, Colony-stimulating factor, GM-CSF, GMCSF, Granulocyte-macrophage colony-stimulating factor, ... ... When stimulated with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4), monocytes yield DCs [ ... Effects of recombinant human granulocyte colony-stimulating factor (CSF), human granulocyte macrophage-CSF, and gibbon ... Interleukin-3 (IL-3) and granulocyte-monocyte-colony-stimulating factor (GM-CSF) stimulate proliferation of human acute myeloid ...
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 3 (IL-3) are pleiotropic hemopoietic growth factors ... The granulocyte-macrophage colony-stimulating factor/interleukin 3 locus is regulated by an inducible cyclosporin A-sensitive ... The granulocyte-macrophage colony-stimulating factor/interleukin 3 locus is regulated by an inducible cyclosporin A-sensitive ... The granulocyte-macrophage colony-stimulating factor/interleukin 3 locus is regulated by an inducible cyclosporin A-sensitive ...
Three-dimensional structure of recombinant human granulocyte-macrophage colony-stimulating factor. ... Three-dimensional structure of recombinant human granulocyte-macrophage colony-stimulating factor. Display Files *FASTA ... R-Factor (All). R-Factor (Observed). R-Work. R-Free. R-Free Selection Details. ...
Colony-stimulating factor levels were measured by a semi-solid tissue culture colony assay with murine bone marrow as the ... This is the first demonstration of an effect of parasitic infection in man on the granulocyte regulatory system, and opens the ... Abstract Studies have been done to determine the levels of human urinary granulocyte colony-stimulating factor in Egyptian ... Urinary Granulocyte Colony-Stimulating Factor in Bilharziasis * * Lotfy Abdel Naby Mahmoud, William A. Robinson, Maureen A. ...
... recombinant human granulocyte/macrophage colony-stimulating factor) in Daviss Drug Guide including dosage, side effects, ... rHu GM-CSF (recombinant human granulocyte/macrophage colony-stimulating factor). Ther. Class.. colony-stimulating factors ... rHu GM-CSF (recombinant human granulocyte/macrophage colony-stimulating factor). Ther. Class.. colony-stimulating factors ...
A Randomized, Double-Masked, Placebo-Controlled Trial of Recombinant Granulocyte Colony-Stimulating Factor Administration to ... A Randomized, Double-Masked, Placebo-Controlled Trial of Recombinant Granulocyte Colony-Stimulating Factor Administration to ... A Randomized, Double-Masked, Placebo-Controlled Trial of Recombinant Granulocyte Colony-Stimulating Factor Administration to ... A Randomized, Double-Masked, Placebo-Controlled Trial of Recombinant Granulocyte Colony-Stimulating Factor Administration to ...
granulocyte colony-stimulating factor • GM-CSF = granulocyte-macrophage colony-stimulating factor • CSF = colony-stimulating ... The hemopoietic colony-stimulating factors, granulocyte colony stimulating factor (G-CSF) and granulocyte-macrophage colony ... 1992) Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF): receptor ... granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor, and interleukin-3) on phagocyte ...
Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute ... Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult ... Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia--a ... encoded search term (What are the benefits of early use of granulocyte colony-stimulating factor (G-CSF) in the treatment of ...
G. J. Elfenbein, "Granulocyte-colony stimulating factor primed bone marrow and granulocyte-colony stimulating factor mobilized ... "Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor exacerbate atherosclerosis in ... The Effect of Granulocyte Colony-Stimulating Factor on the Progression of Atherosclerosis in Animal Models: A Meta-Analysis. ... L. Fan, L. Chen, X. Chen, and F. Fu, "A meta-analysis of stem cell mobilization by granulocyte colony-stimulating factor in the ...
  • Vaccination with irradiated granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting gene-transduced cancer vaccines induces tumoricidal immune responses. (aacrjournals.org)
  • Not to be confused with granulocyte macrophage colony-stimulating factor . (wikipedia.org)
  • The hematopoietic growth factor, granulocyte macrophage colony-stimulating factor (GM-CSF), is considered to play a central role in maintaining chronic inflammation. (rupress.org)
  • Surfactant metabolism in transgenic mice after granulocyte macrophage-colony stimulating factor ablation. (nih.gov)
  • Mice made granulocyte macrophage-colony stimulating factor (GM-CSF)-deficient by homologous recombination maintain normal steady-state hematopoiesis but have an alveolar accumulation of surfactant lipids and protein that is similar to pulmonary alveolar proteinosis in humans. (nih.gov)
  • Lieschke GJ, Burgess AW (1992) Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. (springer.com)
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF) is often used to treat leucopenia. (springer.com)
  • Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. (springer.com)
  • Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. (springer.com)
  • Sargramostim (Leukine®) is a gradulocyte-macrophage colony-stimulating factor (GM-CSF). (bcbsnd.com)
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF) can stimulate proliferation of leukemic blasts and sensitize these cells to the cytotoxic effects of S-phase-specific drugs. (nature.com)
  • 8 , 9 Human granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein which supports proliferation and differentiation of a broad range of hematologic, especially myeloid, precursor cells. (nature.com)
  • Because granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) enhance granulocyte and macrophage number and function, their use in the management of neonatal sepsis may be beneficial. (nih.gov)
  • The granulocyte-macrophage colony-stimulating factor/interleukin 3 locus is regulated by an inducible cyclosporin A-sensitive enhancer. (pnas.org)
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 3 (IL-3) are pleiotropic hemopoietic growth factors whose genes are closely linked and induced in T lymphocytes in a cyclosporin A (CsA)-sensitive fashion. (pnas.org)
  • This study investigates the potential for granulocyte-macrophage colony-stimulating factor (GM-CSF) to effect a clinically relevant increase in neutrophil number when used prophylactically in high-risk preterm neonates, and assesses its safety in this population. (aappublications.org)
  • The hemopoietic colony-stimulating factors, granulocyte colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF), have become standard treatment for preventing chemotherapy-induced neutropenia and accelerating neutrophil recovery after marrow transplantation. (aappublications.org)
  • Outside of the setting of a clinical trial, few data support the use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with ALL. (medscape.com)
  • Regulation of wound healing by granulocyte-macrophage colony-stimulating factor after vocal fold injury. (sigmaaldrich.com)
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF) facilitates epithelial wound healing, and recently, growth factor therapy has been applied to promote tissue repair. (sigmaaldrich.com)
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF), a 22 kDa glycoprotein, was first described as an in vitro inducer of differentiation and proliferation of bone marrow progenitor cells into distinct colonies, including granulocytes and macrophages. (dovepress.com)
  • Isolation of cDNA for a human granulocyte-macrophage colony-stimulating factor by functional expression in mammalian cells. (uniprot.org)
  • A cDNA sequence coding for a human granulocyte-macrophage colony-stimulating factor has been isolated from cDNA libraries prepared from mRNA derived from concanavalin A-activated human T-cell clones. (uniprot.org)
  • Gene Granulocyte-macrophage colony-stimulating factor (GM-CSF), also known as colony stimulating factor 2 (CSF2), is a monomeric glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts that functions as a cytokine. (gentaur.com)
  • Herpes-simplex-virus encoding granulocyte-macrophage colony-stimulating factor (HSV GM-CSF ) is an engineered oncolytic virus. (wjgnet.com)
  • granulocyte-macrophage colony-stimulating factor is a topic covered in the Taber's Medical Dictionary . (tabers.com)
  • Taber's Online , www.tabers.com/tabersonline/view/Tabers-Dictionary/758890/all/granulocyte_macrophage_colony_stimulating_factor. (tabers.com)
  • Lachmann G, Kurth J, von Haefen C, Yuerek F, Wernecke KD, Spies C. In vivo application of Granulocyte-Macrophage Colony-stimulating Factor enhances postoperative qualitative monocytic function. (medsci.org)
  • Granulocyte macrophage colony-stimulating factor (GM-CSF) can be used as a potent stimulator for immune suppressed patients as defined by a decrease of human leukocyte antigen-D related expression on monocytes (mHLA-DR) after surgery. (medsci.org)
  • Recombinant human granulocyte-macrophage colony stimulating factor (sargramostim) as an alternative therapy for fistulizing Crohn's disease. (thefreelibrary.com)
  • We examined whether interferon (IFN)-gamma, a representative Th1 cytokine, modifies the effector functions of human eosinophils stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-5. (unboundmedicine.com)
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been implicated as an important mediator in the pathogenesis of asthma and chronic obstructive pulmonary disease (COPD). (bmj.com)
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a major regulator of inflammatory cells of the myeloid lineage and has been implicated in asthma and COPD. (bmj.com)
  • It has previously been shown that human granulocyte-macrophage colony-stimulating factor (GM-CSF) can be fused to a truncated diphtheria toxin (DT) to produce a recombinant fusion toxin that kills GM-CSF receptor-bearing cells. (bloodjournal.org)
  • We chose to use diphtheria toxin as the toxophore and human granulocyte-macrophage colony-stimulating factor (GM-CSF) as the haptophore or ligand. (bloodjournal.org)
  • Role of granulocyte-macrophage colony stimulating factor (GM-CSF) in the pathogenesis of adult pulmonary histiocytosis X. (bmj.com)
  • Global Markets Directs, Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Pipeline Review, H2 2016, provides in depth analysis on Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted pipeline therapeutics. (researchmoz.us)
  • The report provides comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. (researchmoz.us)
  • Additionally, the report provides an overview of key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics development and features dormant and discontinued projects. (researchmoz.us)
  • To evaluate a dose intensive chemotherapy regimen for the treatment of locally advanced and metastatic breast cancer using granulocyte-macrophage colony-stimulating factor (GM-CSF) to ameliorate chemotherapy-induced toxicity. (knowcancer.com)
  • Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) pipeline Target constitutes close to 11 molecules. (aarkstore.com)
  • It also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics development with respective active and dormant or discontinued projects. (aarkstore.com)
  • Objectives To determine the safety, tolerability and signs of efficacy of MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF), in patients with rheumatoid arthritis (RA). (bmj.com)
  • In a pilot study with five oral cancer patients undergoing radiotherapy (RT) three were given Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) as a protective agent to reduce the mucosal inflammation during radiotherapy. (amrita.edu)
  • Granulocyte-macrophage colony-stimulating factor can stimulate macrophage proliferation via persistent activation of Na+/H+ antiport. (portlandpress.com)
  • Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. (rupress.org)
  • Using granulocyte/macrophage colony-stimulating factor (GM-CSF) and interleukin 4 we have established dendritic cell (DC) lines from blood mononuclear cells that maintain the antigen capturing and processing capacity characteristic of immature dendritic cells in vivo. (rupress.org)
  • Granulocyte-macrophage colony-stimulating factor: involvement in control of Trypanosoma cruzi infection in mice. (asm.org)
  • Synthes Award for Resident Research on Spinal Cord and Spinal Column Injury: granulocyte macrophage colony stimulating factor (GM-CSF) prevents apoptosis and improves functional outcome in experimental spinal cord contusion injury. (harvard.edu)
  • The purpose of our study was to determine the maximally tolerated dose (MTD) and DLT of combined administration of granulocyte macrophage colony-stimulating factor (GM-CSF), low-dose interleukin 2 (IL-2) and IFN-α in patients with progressive metastatic melanoma or renal cell carcinoma (RCC). (aacrjournals.org)
  • Granulocyte-macrophage colony-stimulating factor and tetradecanoyl phorbol acetate induce a distinct, restricted subset of primary-response TIS genes in both proliferating and terminally differentiated myeloid cells. (asm.org)
  • R.W. Lim, B.C. Varnum, and H.R. Herschman, Oncogene 1:263-270, 1987) by granulocyte-macrophage colony-stimulating factor (GM-CSF) and TPA was examined both in a factor-dependent murine cell line, 32D clone 3, and in mature human neutrophils. (asm.org)
  • In the present study, we demonstrate that Mcl-1 is tightly regulated by the granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling pathway. (asm.org)
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3) are two hematopoietic cytokines produced by activated T cells and mast cells that are potent growth factors for multipotential hematopoietic progenitors as well as various other hematopoietic cells ( 2 ). (asm.org)
  • Fourteen patients with advanced solid tumors were included in a phase I trial of recombinant human E. coli derived granulocyte-macrophage colony-stimulating factor (GM-CSF) given daily subcutaneously for 10 consecutive days. (eurekamag.com)
  • To evaluate the serum levels of interleukin-4, interleukin-10, and granulocyte-macrophage colony-stimulating factor at the moment of diagnosis and in early second-trimester serum from women with preeclampsia and from gestational age-matched controls. (ovid.com)
  • Serum levels of granulocyte-macrophage colony-stimulating factor at the moment of diagnosis were detected less frequently (21 compared with 71%, P (ovid.com)
  • In second-trimester serum, granulocyte-macrophage colony-stimulating factor detection rates (20 and 70% respectively, P = .06) and concentrations (0 pg/mL [range 0-32] and 2.5 pg/mL [range 0-37], respectively, P = .08) were lower in the group of preeclampsia, but the differences do not reach statistical significance. (ovid.com)
  • Differences in granulocyte-macrophage colony-stimulating factor support the concept of the existence of an immunologic imbalance as part of the etiologic mechanisms leading to preeclampsia. (ovid.com)
  • Granulocyte-macrophage colony-stimulating factor, often abbreviated to GM-CSF, is a protein secreted by macrophages, T cells, mast cells, endothelial cells and fibroblasts. (pediatriconcall.com)
  • Recombinant Human Granulocyte Macrophage Colony Stimulating Factor produced in Yeast is a single, glycosylated, polypeptide chain containing 127 amino acids and having a molecular mass of 26-32 kDa. (creativebiomart.net)
  • It is recommended to reconstitute the lyophilized Granulocyte Macrophage Colony Stimulating Factor in sterile 18 MΩ-cm H 2 O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions. (creativebiomart.net)
  • Lyophilized Granulocyte Macrophage Colony Stimulating Factor although stable at room temperature for 3 weeks, should be stored desiccated below -18 °C . Upon reconstitution GMCSF should be stored at 4 °C between 2-7 days and for future use below -18 °C . For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). (creativebiomart.net)
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces the proliferation and maturation of immature myeloid progenitor cells and primes mature cell function in phagocytes. (ovid.com)
  • Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers. (pubmedcentralcanada.ca)
  • The granulocyte colony-stimulating factor receptor is present on precursor cells in the bone marrow, and, in response to stimulation by G-CSF, initiates cell proliferation and differentiation into mature neutrophilic granulocytes and macrophages. (wikipedia.org)
  • reference 10), necessary for T cell activation by foreign proteins, induction of monocyte/macrophage MHC class II expression ( 11 ), enhancement of the phagocytic activity and antigen presenting function of macrophages and/or microglia ( 12 )( 13 ), priming of monocytes for cytokine production ( 14 )( 15 ), and enhancement of macrophage and granulocyte adherence ( 16 )( 17 ). (rupress.org)
  • A protein that stimulates white blood cells, especially granulocytes, macrophages, and cells that become platelets, to multiply and mature. (nih.gov)
  • Granulocyte/macrophage colony-stimulating factors are cytokines that act in hematopoiesis by controlling the production, differentiation, and function of 2 related white cell populations of the blood, the granulocytes and the monocytes-macrophages. (uniprot.org)
  • A naturally occurring protein that stimulates the production of granulocytes and macrophages by stem cells and is used as a drug by some immunosuppressed individuals. (wordnik.com)
  • Also the recently reported G-CSF-induced maturation of monocytes/macrophages [ 7 ] can be relevant to the role of this growth factor in acute radiation syndrome. (mdpi.com)
  • Granulocyte Colony-Stimulating Factor, or G-CSF, is a growth factor that is considered the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines. (cellsciences.com)
  • Infliximab is a chimeric monoclonal immunoglobulin antibody (igGl) against tumor necrosis factor, a product of macrophages (3). (thefreelibrary.com)
  • It plays an important role in controls the production, differentiation, and function of granulocytes and macrophages. (aarkstore.com)
  • These results lead us to suggest that the Na+/H+ antiport has a role in macrophage proliferation and in the regulation of intracellular pH during the oxidative burst stimulated by PAF and other agonists, and that differential mechanisms whereby this antiport is regulated exist in macrophages. (portlandpress.com)
  • GMCSF is a cytokine that controls the production, differentiation, and function of granulocytes and macrophages. (creativebiomart.net)
  • GM-CSF stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes. (creativebiomart.net)
  • G-CSF also stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils. (wikipedia.org)
  • White blood cells The G-CSF-receptor is present on precursor cells in the bone marrow, and, in response to stimulation by G-CSF, initiates proliferation and differentiation into mature granulocytes. (wikipedia.org)
  • It also stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils. (wikidoc.org)
  • 10 By stimulating proliferation of leukemic blasts, GM-CSF can sensitize these cells to the cytotoxic effects of S-phase-specific drugs, such as cytarabine. (nature.com)
  • In vitro studies have generally confirmed the impact of growth factors on leukemic cell proliferation and sensitivity to chemotherapy. (nature.com)
  • Growth factors are polypeptides essentially involved in regulating survival, proliferation, maturation, and outgrowth of developing neuronal cells. (ahajournals.org)
  • G-CSF stimulates the proliferation, survival, and maturation of cells committed to the neutrophilic granulocyte (NG) lineage through binding to the specific G-CSF receptor (G-CSFR). (ahajournals.org)
  • Complex subunit associated factors are involved in hybridoma growth, Eosinohils, eritroid proliferation and derived from promotor binding stimulating subunits on the DNA binding complex. (gentaur.com)
  • Granulocyte Colony Stimulating Factor (G-CSF) is a pleiotropic cytokine best known for its specific effects on the proliferation, differentiation, and activation of hematopoietic cells of the neutrophilic granulocyte lineage. (cellsciences.com)
  • The effects of two such agents, granulocytemacrophage colony-stimulating factor (GM-CSF, which stimulates proliferation) and platelet-activating factor (PAF, which stimulates chemotaxis and bactericidal activity), on cellular signal transduction mechanisms were compared. (portlandpress.com)
  • Cytokines belong to a family of growth factors that play an important role in regulating the viability, differentiation, proliferation, and function of various hematopoietic cells ( 2 ). (asm.org)
  • Additionally, GM-CSF can also stimulate the proliferation of a number of tumor cell lines, including osteogenic sarcoma, carcinoma and adenocarcinoma cell lines. (creativebiomart.net)
  • In nonneutropenic patients, G-CSF may stimulate neutrophil production, enhancing the inflammatory response ( 16 , 17 ). (diabetesjournals.org)
  • Neutrophil migration inhibition factor from T lymphocytes (NIF-T) is a lymphokine that acts to localize granulocytes. (sciencemag.org)
  • In this setting, time to neutrophil recovery is shortened by growth factor administration. (nature.com)
  • In a Groupe d'Etude et de Traitement de la Leucemie Aigue Lymphoblastique de l'Adulte (GET-LALA) study, in patients who received G-CSF, GM-CSF, or no growth factor during induction therapy, the median time for neutrophil recovery was 17 days for G-CSF, 18 days for GM-CSF, and 21 days for no growth factors. (medscape.com)
  • To study a possible role of neutrophils in granulocyte colony-stimulating factor (G-CSF) induced hematopoietic mobilization, we assessed the number of circulating CD34(+) cells in healthy allogeneic stem cell donors on days 3, 4, and 5 of mobilization for comparison with the number of peripheral blood neutrophils and the plasma levels of IL-8, Flt3 ligand (FL), matrix metalloproteinase-9 (MMP-9), and human neutrophil elastase (HNE). (rug.nl)
  • However, because stem cell numbers could not be predicted by proteolytic enzyme levels and/or neutrophil numbers, other undefined factors may be more important. (rug.nl)
  • 8 GM-CSF is a pleiotrophic and proinflammatory cytokine that stimulates myelopoiesis, promotes leucocyte survival and activation, and regulates mucosal immunity and inflammation in part via modulation of Toll-like receptor-4 9 and neutrophil function. (bmj.com)
  • Granulocyte-colony stimulating factor (G-CSF) increases the release of neutrophil endothelial progenitor cells from the bone marrow and improves neutrophil functions, which are often impaired in people with diabetes. (cochrane.org)
  • Increases of granulocyte, neutrophil and eosinophil counts had a similar pattern with a weaker response at 1000 mu-g/m-2 (two patients who completed the cycle). (eurekamag.com)
  • In order to clarify the signal transduction mechanisms of growth suppression during G-CSF induced neutrophil differentiation, gene expressions of cell-cycle regulatory proteins and transcription factors which are involved in granulocyte differentiation were examined in neutrophil progenitor cells GM-162M and 32Dcl3 by Northern blot hybridization. (nii.ac.jp)
  • Functionally, it is a cytokine and hormone, a type of colony-stimulating factor, and is produced by a number of different tissues. (wikipedia.org)
  • Granulocyte colony-stimulating factor (G-CSF) is a member of the cytokine family of growth factors. (cmaj.ca)
  • On the other hand, GM-CSF deficiency leads to various immune dysfunctions and the current utilization of GM-CSF as haematopoietic factor might be an accurate but very incomplete indication for a cytokine with vast clinical potential. (springer.com)
  • It is a glycoprotein, growth factor or cytokine produced by a number of different tissues to stimulate the bone marrow to produce granulocytes and stem cells . (wikidoc.org)
  • Granulocyte colony-stimulating factor (G-CSF) is a principle cytokine controlling granulocyte number. (springer.com)
  • We have recently identified granulocyte-colony stimulating factor (G-CSF) as a soluble cytokine that alters the behavioral response to cocaine and which increases dopamine release from the ventral tegmental area (VTA). (mdpi.com)
  • Granulocyte colony-stimulating factor (G-CSF), a 20-kDa protein, is a member of the cytokine family of growth factors, along with tumor necrosis factor-α (TNF-α) and the interleukins. (ahajournals.org)
  • Therefore, monocytic and T cell function such as mHLA-DR, tumor necrosis factor alpha (TNF-α) after LPS stimulation, T cell counts, Th1/Th2 specific cytokine production and the ratio of the number of Th17 cells to the number of Treg cells were studied after postoperative GM-CSF application. (medsci.org)
  • GM-CSF is a cytokine that functions as a white blood cell growth factor. (pediatriconcall.com)
  • Granulocyte colony-stimulating factor (G-CSF or GCSF), also known as colony-stimulating factor 3 (CSF 3), is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream. (wikipedia.org)
  • Granulocyte Colony-Stimulating Factor ( G-CSF or GCSF ) is a colony-stimulating factor hormone. (wikidoc.org)
  • The granulocyte colony-stimulating factor receptor (G-CSF-R) also known as CD114 (Cluster of Differentiation 114) is a protein that in humans is encoded by the CSF3R gene. (wikipedia.org)
  • G-CSF-R is a cell-surface receptor for the granulocyte colony-stimulating factor (G-CSF). (wikipedia.org)
  • Granulocyte colony-stimulating factor receptor has been shown to interact with Grb2, HCK and SHC1. (wikipedia.org)
  • We now report that DT388-GM-CSF induces apoptosis and inhibition of colony formation in semisolid medium in receptor positive cells, and that the induction of apoptosis correlates with GM-CSF-receptor occupancy at low ligand concentrations. (bloodjournal.org)
  • DT388-GM-CSF at 4 × 10 −9 mol/L inhibited colony formation 1.5 to 3.0 logs for receptor positive cell lines. (bloodjournal.org)
  • TIS1 is a member of the nuclear receptor supergene family that codes for ligand-dependent transcription factors. (asm.org)
  • Signal transduction mechanisms through granulocyte colony-stimulating factor receptor. (nii.ac.jp)
  • during treatment with chemotherapy to stimulate the bone marrow to make white blood cells, called neutrophils. (macmillan.org.uk)
  • Recombinant Human Granulocyte-Colony Stimulating Factor is a single non-glycosylated polypeptide chain containing 175 amino acids. (cellsciences.com)
  • A glycosylated recombinant human granulocyte colony stimulating factor" by Roslyn Varki, Ed Pequignot et al. (jefferson.edu)
  • A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study. (jefferson.edu)
  • BACKGROUND: AVI-014 is an egg white-derived, recombinant, human granulocyte colony-stimulating factor (G-CSF). (jefferson.edu)
  • PURPOSE: The aim of this study is to determine and compare the effects of adjunctive therapy with different doses of recombinant human granulocyte-colony stimulating factor(rhG-CSF) on reversing sepsis-associated neonatal neutropenia, and their survival rate in a group I/II-type trial. (koreamed.org)
  • 4 GM-CSF can also act on relatively early progenitor cells and interacts with erythropoietin to stimulate eosinophil and megakaryocyte colony formation in vitro. (dovepress.com)
  • Besides granulocyte-macrophage progenitors, GM-CSF is also a growth factor for erythroid, megakaryocyte and eosinophil progenitors. (creativebiomart.net)
  • Colony-stimulating factor levels were measured by a semi-solid tissue culture colony assay with murine bone marrow as the target cell source. (ajtmh.org)
  • The response to granulocyte-colony stimulating factor mobilization was investigated in a murine WAS knock-out model of the disease, by measuring haematological parameters, circulation and engraftment of hematopoietic progenitor/stem cells. (haematologica.org)
  • Originally identified as a differentiation factor for murine leukemic cells. (drugfuture.com)
  • Recently biosimilars of granulocyte-colony-stimulating factor (G-CSF) became available for prophylaxis and treatment of postchemotherapy neutropenia and for mobilization of peripheral blood CD34+ cells for either autologous or allogeneic hematopoietic stem cell transplant. (wiley.com)
  • PAF can stimulate inositol lipid hydrolysis leading to Ca2+ mobilization. (portlandpress.com)
  • We hypothesized that mobilization of HSC by granulocyte colony-stimulating factor (G-CSF) should create temporary space in bone marrow niches to improve engraftment and thereby B-cell reconstitution. (eur.nl)
  • Thus a human lymphokine (NIF-T) that modulates the activities of mature neutrophilic granulocytes is also a colony-stimulating factor acting on precursors to induce growth and differentiation of new effector cells. (sciencemag.org)
  • Growth factors which have been studied both in the laboratory and in clinical trials include GM-CSF, granulocyte-colony stimulating factor (G-CSF), and interleukin-3 (IL-3). (nature.com)
  • Plasma levels of stromal cell derived factor 1, angiopoietin 1, interleukin 8 and tumour necrosis factor α decreased after a symptom limited EST while vascular endothelial growth factor and platelet derived growth factor remained unchanged. (bmj.com)
  • G-CSF stimulates the production of granulocytes, a type of white blood cell. (wikipedia.org)
  • G-CSF stimulates the bone marrow to make more blood cells. (macmillan.org.uk)
  • This will stimulate your bone marrow to make stem cells and increase the number of stem cells in the blood. (macmillan.org.uk)
  • Granulocyte colony-stimulating factor (G-CSF) is an endogenous hematopoietic growth factor that induces terminal differentiation and release of neutrophils from the bone marrow ( 8 ). (diabetesjournals.org)
  • Granulocyte colony-stimulating factor (G-CSF) is a naturally occurring glycoprotein that is synthesized by stromal cells in bone marrow. (springer.com)
  • The NIF-T was found to potently stimulate the growth of granulocyte and macrophage colonies from human bone marrow and colony formation by the KG-1 myeloid leukemia cell line. (sciencemag.org)
  • G-CSF then stimulates the bone marrow to pulse them out of the marrow into the blood. (wikidoc.org)
  • G-CSFs are a blood growth factor that stimulates the bone marrow to produce more infection-fighting white blood cells known as neutrophils. (bcbsnd.com)
  • The role of the sensitivity of bone marrow cells to, and the pharmacokinetics of granulocyte colony-stimulating factor (G-CSF) on the rhythm of leukocyte-increasing effect was investigated in ICR male mice housed under a standardized light-dark cycle (lights on at 0700, off at 1900). (aspetjournals.org)
  • 01). Bone marrow cultures obtained at two times of day resulted in different numbers of myeloid colonies even when treated with the same concentrations of G-CSF in vitro . (aspetjournals.org)
  • Highlighted are the topics of its real or anticipated use in radiation accident victims, the timing of its administration, the possibilities of combining G-CSF with other drugs, the ability of other agents to stimulate endogenous G-CSF production, as well as of the capability of this growth factor to ameliorate not only the bone marrow radiation syndrome but also the gastrointestinal radiation syndrome. (mdpi.com)
  • In this multicenter retrospective study, the outcomes of 234 patients with myelodysplastic syndrome (MDS) who underwent transplantation between 1995 and 1999 from HLA-identical siblings were analyzed according to the hematopoietic stem cell source used, that is, bone marrow (BM, n = 132) or granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells (PBPCs, n = 102). (bloodjournal.org)
  • In chronic myeloid and acute leukemia, the use of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells (PBPCs) has been associated with faster hematopoietic recovery when compared with bone marrow. (bloodjournal.org)
  • Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow. (stembook.org)
  • Sheridan JW, Metcalf D. A low molecular weight factor in lung-conditioned medium stimulating granulocyte and monocyte colony formation in vitro. (springer.com)
  • GM-CSF was initially characterized as a growth factor that can support the in vitro colony formation of granulocyte-macrophage progenitors. (creativebiomart.net)
  • GM-CSF stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. (pediatriconcall.com)
  • Asano S, Urabe A, Okabe T et al (1977) Demonstration of granulopoietic factor(s) in the plasma of nude mice transplanted with a human lung cancer and in the tumor tissue. (springer.com)
  • Tani K, Ozawa K, Ogura H et al (1990) Expression of granulocyte and granulocyte-macrophage colony-stimulating factors by human non-hematopoietic tumor cells. (springer.com)
  • Myeloid-derived suppressor cells (MDSCs) have been shown to contribute to tumor escape from host immune surveillance and to cancer progression by production of tumor-promoting soluble factors. (springer.com)
  • Mouse granulocyte-colony stimulating factor (G-CSF) was first recognised and purified in Walter and Eliza Hall Institute, Australia in 1983, and the human form was cloned by groups from Japan and Germany/United States in 1986. (wikipedia.org)
  • Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. (wikidoc.org)
  • Studies have been done to determine the levels of human urinary granulocyte colony-stimulating factor in Egyptian patients with active bilharziasis. (ajtmh.org)
  • By assaying the cell supernatants, we identified clones encoding a factor that stimulates the formation of granulocyte and macrophage colonies from human progenitor cells. (uniprot.org)
  • Molgradex offers a novel treatment approach for NTM infection by stimulating the human immune system in the lungs with localized delivery of GM-CSF, directly into the site of infection. (benzinga.com)
  • Instead, it stimulates the human immune response without targeting the bacteria directly, thus avoiding the problem of inducing antibiotic resistance. (benzinga.com)
  • Purification and characterization of human granulocyte colony-stimulating factor (G-CSF). (nii.ac.jp)
  • Metabolism of platelet-activating factor in human haematopoietic cell lines. (portlandpress.com)
  • Gene expression profile of human endometrial receptivity: comparison between natural and stimulated cycles for the same patients. (ebscohost.com)
  • It's also possible that C/EBPα and/or C/EBPε transcription factors control the gene expression … More of these CDK inhibitors. (nii.ac.jp)
  • This research report will present a complete account of the Global granulocyte colony stimulating factor sales market report 2017 is the ideal amalgamation of documented market information, expert knowledge sets, demonstrated research procedures, and the aim of furnishing its readers with a bare all assessment of the market's development prospects for the coming years. (qyresearchreports.com)
  • The geographical assessment of the Global granulocyte colony stimulating factor sales market report 2017 can be portrayed as a widely inclusive survey of the key regions, from the points of view of the regions mentioned in addition to the player base in every area, and the general end user reports for them. (qyresearchreports.com)
  • The competitive scene of the Global granulocyte colony stimulating factor sales market report 2017 is unquestionably an intriguing aspect of the market, made simple to examine on account of the endeavors put in by the investigators for this report. (qyresearchreports.com)
  • In the recent times, the global market for United states granulocyte colony stimulating factor market report 2017 has surfaced as one of the most promising markets in the pharmaceutical industry, thanks to the significant rise in research and development activities by leading vendors of United states granulocyte colony stimulating factor market report 2017 across the world. (qyresearchreports.com)
  • Manufacturers have turned to technological innovations and data-driven customization to satisfy the augmenting consumer demand for efficiency and more accuracy in results, leading to an increased usage of technology in the United states granulocyte colony stimulating factor market report 2017 production processes, which is also reflecting positively on the growth of this market. (qyresearchreports.com)
  • The research report on the United states granulocyte colony stimulating factor market report 2017 is an analytical study which comprehensively analyzes the competitive framework of this market. (qyresearchreports.com)
  • Using a number of effective assessment tools, such as porter's five forces and value chain analysis, it performs in-depth analyses of the production and supply as well as the demand and sales of United states granulocyte colony stimulating factor market report 2017 and provides deep insights into the future prospects of this market. (qyresearchreports.com)
  • The study begins with a detailed overview of the market for United states granulocyte colony stimulating factor market report 2017, including the definition, classification, and industry chain structure of United states granulocyte colony stimulating factor market report 2017, and move forward to cover every aspect of this market, counting several criteria based on which the market is classified. (qyresearchreports.com)
  • With chemical industry undergoing a phase of technological disruption, innovations in products are likely to shape the future of the United states granulocyte colony stimulating factor market report 2017. (qyresearchreports.com)
  • Further, it offers an estimation of the market size in terms of value (US$) and in volume (kilo tons) and talks about the key segments and the geographical subdivisions of the market for United states granulocyte colony stimulating factor market report 2017 in details. (qyresearchreports.com)
  • It provides in-depth information on the development trends and the policies and regulations, concerning United states granulocyte colony stimulating factor market report 2017, implemented in each of the geographical segments. (qyresearchreports.com)
  • The predominant applications of the United states granulocyte colony stimulating factor market report 2017 have also been discussed at length in this research study. (qyresearchreports.com)
  • With all these analyses and information, this report can act as a valuable guide to readers looking to gain a clear understanding of all the factors that are influencing the market for United states granulocyte colony stimulating factor market report 2017 at present and are projected to remain doing so over the forecast period. (qyresearchreports.com)
  • This is the first demonstration of an effect of parasitic infection in man on the granulocyte regulatory system, and opens the way for future studies in this area. (ajtmh.org)
  • A recent study of our research group aimed to stimulate postoperative immune function using GM-CSF and found an increase of mHLA-DR as well as a decrease of infection days after application of GM-CSF [ 5 ]. (medsci.org)
  • To examine the effects of adjunctive G-CSF compared with placebo or no growth factor added to usual care on rates of infection, cure and wound healing in people with diabetes who have a foot infection. (cochrane.org)
  • Neurons G-CSF can also act on neuronal cells as a neurotrophic factor. (wikipedia.org)
  • 5-10 micrograms/kg/day) for the first 7-10 days following transplantation, targeting a blood absolute granulocyte count of between 10,000 and 20,000 cells/mm3. (nih.gov)
  • Because granulocyte colony-stimulating factor (G-CSF) has anti-inflammatory and neuroprotective properties and is known to mobilize stem cells, it may be useful in the treatment of acute ischemic stroke. (cmaj.ca)
  • G-CSF stimulates the production of white blood cells (WBC). (wikidoc.org)
  • The use of growth factors to drive malignant cells into cell cycle and increase sensitivity to chemotherapy has been attempted in a variety of settings. (nature.com)
  • In addition, EC cells stimulated with GM-CSF were more likely to have suppressed epithelial-to-mesenchymal transition (EMT), accompanied by increased E-cadherin and decreased vimentin expression. (dovepress.com)
  • These results demonstrate that identification of full-length cDNAs for many colony-stimulating factors may be achieved entirely on the basis of detecting the functional polypeptide produced in mammalian cells. (uniprot.org)
  • Dendritic cells (DCs) have a unique ability to stimulate naive T cells. (jimmunol.org)
  • Freshly sorted CD11c + but not CD11c − cells stimulate CD4 + T cells in an allogeneic MLR, whereas only the CD11c − cells can be induced to secrete high levels of IFN-α, in response to influenza virus. (jimmunol.org)
  • These two subsets up-regulate MHC class II costimulatory molecules as well as the DC maturation marker DC-lysosome-associated membrane protein, and they stimulate naive, allogeneic CD4 + T cells efficiently. (jimmunol.org)
  • Cells were incubated with varying concentrations of recombinant fusion toxin for 48 hours and incorporation of 3 H-leucine (protein synthesis), segmentation of nuclei after DAPI staining (apoptosis), and colony formation in 0.2% agarose (clonogenicity) were measured. (bloodjournal.org)
  • In spite of these anomalies, the administration of granulocyte-colony stimulating factor mobilizes progenitor/stem cells in WAS knock-out mice to the same level and with the same kinetic as in wild-type control mice. (haematologica.org)
  • Upon deprivation of survival factor from TF-1 myeloid progenitor cells, Mcl-1 levels quickly dropped prior to visible detection of apoptosis of these cells. (asm.org)
  • The authors showed that granulocyte colony-stimulating factor (G-CSF) increased renal infiltration of myeloid-derived suppressor cells after ischemia-reperfusion injury. (asnjournals.org)
  • Background Granulocyte colony-stimulating factor (G-CSF) can increase populations of myeloid-derived suppressor cells, innate immune suppressors that play an immunoregulatory role in antitumor immunity. (asnjournals.org)
  • GM-CSF stimulated MAP kinase activation in both the undifferentiated and differentiated HL-60 cells. (ovid.com)
  • Hematopoietic growth factor that stimulates the development of committed progenitor cells to neutrophils and enhances the functional activities of the mature end-cell. (drugfuture.com)
  • Results of some clinical trials indicate that plerixafor in addition to granulocyte colony-stimulating factors (G-CSF) compared to G-CSF only could lead to an increased mobilisation and release of CD34-positive cells, facilitating effective apheresis. (uzh.ch)
  • It is thought that stability of the G-CSF mRNA is regulated by an RNA element called the G-CSF factor stem-loop destabilising element. (wikipedia.org)
  • Granulocyte colony-stimulating factor exacerbates hematopoietic stem cell injury after irradiation. (stembook.org)
  • Granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cell (PBPC) collections are increasingly emerging as the graft of choice in many centers for autologous transplantation, and with increasing frequency for allogeneic transplantation. (cun.es)
  • Granulocyte colony-stimulating factor (G-CSF) increases the number of circulating granulocytes and decreases TNF production while improving survival in sepsis models. (nih.gov)
  • Univariate and logistic regression analysis of risk factors for sepsis and rejection revealed no difference between the two patient groups. (nih.gov)
  • We performed a randomized, double-masked, parallel-groups, placebo-controlled trial of recombinant granulocyte colony-stimulating factor (rG-CSF) administration to 44 preterm neonates who had blood cultures obtained and antibiotics begun because of the clinical diagnosis of early-onset sepsis. (aappublications.org)
  • Five-day prophylactic GM-CSF completely abolishes postnatal neutropenia and sepsis-induced neutropenia in preterm neonates at high risk of sepsis, and so removes an important risk factor for sepsis and sepsis-related mortality.GM-CSF, preterm neonates, neutropenia, sepsis. (aappublications.org)
  • 1 Attempts to prevent sepsis or reduce sepsis-related mortality using intravenous immunoglobulin have failed to make a major impact 2 and attention has recently turned to the potential enhancement of phagocyte immunity using the hemopoietic colony-stimulating factors. (aappublications.org)
  • Objectives: Granulocyte-colony stimulating factor (G-CSF) is known to induce the myeloid-derived suppressor cell (MDSC) to stimulate the progression of uterine cervical cancer. (aacrjournals.org)
  • Granulocyte colony-stimulating factor treatment for cyclophosphamide-induced severe neutropenia in Wegener's granulomatosis. (nih.gov)
  • Consequently, we discuss the pharmacological use of granulopoiesis stimulating factors not only in the context of febrile neutropenia but also from the perspective of MDSC-dependent and MDSC-independent mechanisms of immunosuppression and cancer angiogenesis. (springer.com)
  • Recombinant granulocyte colony-stimulating factor (rG-CSF) is a myeloid growth factor that is widely used in haematology to recover neutropenia secondary to myelosuppressive chemotherapy. (hindawi.com)
  • Are Granulocyte Colony-Stimulating Factors Beneficial in Treating Diabetic Foot Infections? (diabetesjournals.org)
  • OBJECTIVE -To assess the value of granulocyte colony-stimulating factor (G-CSF) as adjunctive therapy for diabetic foot infections. (diabetesjournals.org)
  • These factors help explain reported clinical failure rates for diabetic foot infections of 20-30% ( 3 , 5 - 7 ). (diabetesjournals.org)
  • Cruciani M, Lipsky BA, Mengoli C, de Lalla F. Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections. (cochrane.org)
  • The hematopoietic growth factor, GM-CSF, was first considered to be proinflammatory because of its ability to stimulate macrophage plasminogen activator activity ( 8 ). (rupress.org)